{"id":29595,"date":"2025-05-04T14:35:34","date_gmt":"2025-05-04T12:35:34","guid":{"rendered":"https:\/\/semaxpolska.com\/?page_id=29595"},"modified":"2026-09-04T11:49:21","modified_gmt":"2026-09-04T09:49:21","slug":"dopamins-un-ta-ietekme-uz-musu-ikdienas-dzivi","status":"publish","type":"post","link":"https:\/\/bioevidencehub.com\/lv\/dopamina-i-jej-wplyw-na-nasze-codzienne-zycie\/","title":{"rendered":"Dopam\u012bns un t\u0101 ietekme uz m\u016bsu ikdienas dz\u012bvi"},"content":{"rendered":"<h2>Satura r\u0101d\u012bt\u0101js<\/h2>\n<ol>\n<li><a href=\"#_Toc195560237\">Kas ir dopam\u012bns? 1<\/a><\/li>\n<li><a href=\"#_Toc195560238\">Dopam\u012bns k\u0101 neiromediators un hormons. 1<\/a><\/li>\n<li><a href=\"#_Toc195560239\">Dopam\u012bna \u0137\u012bmisk\u0101 daba. 2<\/a><\/li>\n<li><a href=\"#_Toc195560240\">Fiziolo\u0123isk\u0101s un biolo\u0123isk\u0101s \u012bpa\u0161\u012bbas. 2<\/a><\/li>\n<li><a href=\"#_Toc195560241\">Darb\u012bbas meh\u0101nisms. 2<\/a><\/li>\n<li><a href=\"#_Toc195560242\">Dopam\u012bna receptori. 2<\/a><\/li>\n<li><a href=\"#_Toc195560243\">Dopam\u012bns centr\u0101laj\u0101 nervu sist\u0113m\u0101.... 3<\/a><\/li>\n<li><a href=\"#_Toc195560244\">Dopam\u012bns perif\u0113raj\u0101 sist\u0113m\u0101.... 3<\/a><\/li>\n<li><a href=\"#_Toc195560245\">Dopam\u012bns un t\u0101 ietekme uz citiem neiromediatoriem 4<\/a><\/li>\n<li><a href=\"#_Toc195560246\">Dopam\u012bna un seroton\u012bna kombin\u0101cija: 4<\/a><\/li>\n<li><a href=\"#_Toc195560247\">Dopam\u012bna un noradrenal\u012bna kombin\u0101cija: 4<\/a><\/li>\n<li><a href=\"#_Toc195560248\">Dopam\u012bna un glutam\u0101ta kombin\u0101cija: 4<\/a><\/li>\n<li><a href=\"#_Toc195560249\">Dopam\u012bna un GABA kombin\u0101cija: 5<\/a><\/li>\n<li><a href=\"#_Toc195560250\">Dopam\u012bns un kortizols 5<\/a><\/li>\n<li><a href=\"#_Toc195560251\">Dopam\u012bns un oksitoc\u012bns. 5<\/a><\/li>\n<li><a href=\"#_Toc195560252\">Dopam\u012bns un endorf\u012bni. 5<\/a><\/li>\n<li><a href=\"#_Toc195560253\">Dopam\u012bns un acetilhol\u012bns. 6<\/a><\/li>\n<li><a href=\"#_Toc195560254\">Garast\u0101vok\u013ca sv\u0101rst\u012bbas ar dopam\u012bna l\u012bmeni. 6<\/a><\/li>\n<li><a href=\"#_Toc195560255\">Dopam\u012bns un atalgojuma sist\u0113ma. 6<\/a><\/li>\n<li><a href=\"#_Toc195560256\">Dopam\u012bns un \"baudas palielin\u0101\u0161anas\" \u0137\u0113de. 6<\/a><\/li>\n<li><a href=\"#_Toc195560257\">Dopam\u012bns un stresa reakcija. 7<\/a><\/li>\n<li><a href=\"#_Toc195560258\">Dopam\u012bns un motiv\u0101cijas sist\u0113ma 7<\/a><\/li>\n<li><a href=\"#_Toc195560259\">Dopam\u012bns un \"hedonisma treadmill\". 7<\/a><\/li>\n<li><a href=\"#_Toc195560260\">Dopam\u012bns un miegs. 7<\/a><\/li>\n<li><a href=\"#_Toc195560261\">Dopam\u012bna receptoru stimul\u0101cija, lai modul\u0113tu dopam\u012bner\u0123isko iedarb\u012bbu. 8<\/a><\/li>\n<li><a href=\"#_Toc195560262\">Dopam\u012bner\u0123isk\u0101 reakcija un ietekme. 8<\/a><\/li>\n<li><a href=\"#_Toc195560263\">\u0100r\u0113jie faktori, kas stimul\u0113 dopam\u012bna receptorus. 8<\/a><\/li>\n<li><a href=\"#_Toc195560264\">Iek\u0161\u0113jie faktori, kas stimul\u0113 dopam\u012bna receptorus. 9<\/a><\/li>\n<li><a href=\"#_Toc195560265\">Siner\u0123iska iedarb\u012bba un kombin\u0113ti stimuli. 9<\/a><\/li>\n<li><a href=\"#_Toc195560266\">Dopam\u012bna atpaka\u013csaistes inhib\u012bcija. 10<\/a><\/li>\n<li><a href=\"#_Toc195560267\">Dopam\u012bna atpaka\u013csaistes inhib\u012bcijas meh\u0101nisms. 10<\/a><\/li>\n<li><a href=\"#_Toc195560268\">Vielas, kas kav\u0113 dopam\u012bna atpaka\u013csaist\u012b\u0161anos. 10<\/a><\/li>\n<li><a href=\"#_Toc195560269\">Dopam\u012bna atpaka\u013csaistes inhib\u012bcijas ietekme. 11<\/a><\/li>\n<li><a href=\"#_Toc195560270\">Papildin\u0101jumi dopam\u012bna l\u012bme\u0146a paaugstin\u0101\u0161anai. 11<\/a><\/li>\n<li><a href=\"#_Toc195560271\">Bromant\u0101na ietekme uz dopam\u012bna l\u012bmeni. 12<\/a><\/li>\n<li><a href=\"#_Toc195560272\">Aniracet\u0101ma ietekme uz dopam\u012bna l\u012bmeni. 13<\/a><\/li>\n<li><a href=\"#_Toc195560273\">Teakr\u012bna ietekme uz dopam\u012bna l\u012bmeni. 13<\/a><\/li>\n<li><a href=\"#_Toc195560274\">Mucuna ietekme uz dopam\u012bna l\u012bmeni. 14<\/a><\/li>\n<li><a href=\"#_Toc195560275\">Dopam\u012bna l\u012bme\u0146a noteik\u0161ana - dopam\u012bner\u0123isk\u0101s iedarb\u012bbas stimul\u0113\u0161ana! 15<\/a><\/li>\n<li><a href=\"#_Toc195560276\">Smadze\u0146u hacks, lai palielin\u0101tu dopam\u012bna l\u012bmeni - no neirozin\u0101tnieka perspekt\u012bvas.... 16<\/a><\/li>\n<li><a href=\"#_Toc195560277\">Iecien\u012btu \u0113dienu (vai saldumu) \u0113\u0161ana 16<\/a><\/li>\n<li><a href=\"#_Toc195560278\">Soci\u0101lo mediju dopam\u012bna aizpl\u016b\u0161ana. 16<\/a><\/li>\n<li><a href=\"#_Toc195560279\">Aukst\u0101 du\u0161a. 16<\/a><\/li>\n<li><a href=\"#_Toc195560280\">Saules gaismas iedarb\u012bba. 16<\/a><\/li>\n<li><a href=\"#_Toc195560281\">Atsauces: 16<\/a><\/li>\n<\/ol>\n<h2>Kas ir dopam\u012bns?<\/h2>\n<p>Dopam\u012bns ir \u0137\u012bmiska viela, kas darbojas gan k\u0101 neiromediators, gan k\u0101 hormons. Tam ir svar\u012bga loma vair\u0101kos svar\u012bgos organisma procesos, tostarp kust\u012bb\u0101s, motiv\u0101cij\u0101, priek\u0101 un atalgojum\u0101. Dopam\u012bns ir da\u013ca no kateholam\u012bnu grupas, kur\u0101 ietilpst ar\u012b citas svar\u012bgas \u0137\u012bmisk\u0101s vielas, piem\u0113ram, noradrenal\u012bns (norepinefr\u012bns) un adrenal\u012bns (epinefr\u012bns). \u0160\u012bm viel\u0101m ir iz\u0161\u0137iro\u0161a noz\u012bme da\u017e\u0101du \u0137erme\u0146a un smadze\u0146u darb\u012bbas aspektu regul\u0113\u0161an\u0101, s\u0101kot no garast\u0101vok\u013ca un beidzot ar kust\u012bbu kontroli. <a href=\"https:\/\/www.nature.com\/articles\/s41593-018-0152-y\" target=\"_blank\" rel=\"noopener\"><sup>(1)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns k\u0101 neirotransmiters un hormons<\/h3>\n<h4>1. k\u0101 neirotransmiters:<\/h4>\n<p>Neirotransmiters ir molekula, kas p\u0101rraida sign\u0101lus starp nervu \u0161\u016bn\u0101m (neironiem) caur sinaps\u0113m (spraug\u0101m starp neironiem). Dopam\u012bns veidojas smadzen\u0113s un izdal\u0101s no neironiem, kur tas sazin\u0101s ar citiem neironiem, pal\u012bdzot regul\u0113t da\u017e\u0101das funkcijas, s\u0101kot ar kust\u012bb\u0101m un beidzot ar emociju apstr\u0101di. Smadzen\u0113s dopam\u012bns galvenok\u0101rt veidojas t\u0101d\u0101s zon\u0101s k\u0101 meln\u0101 mat\u0113rija un ventr\u0101l\u0101 tegment\u0101l\u0101 zona (VTA) - zon\u0101s, kas saist\u012btas ar atl\u012bdz\u012bbas apstr\u0101di un kust\u012bbu kontroli. <a href=\"https:\/\/books.google.com.pk\/books?hl=en&amp;lr=&amp;id=e4kLiI_kSGUC&amp;oi=fnd&amp;pg=PP1&amp;dq=dopamine+as+neurotransmitter&amp;ots=pDruwGaE5j&amp;sig=wGlK1uOpvpmB0c7ulnNIXApSyVg&amp;redir_esc=y#v=onepage&amp;q=dopamine%20as%20neurotransmitter&amp;f=false\" target=\"_blank\" rel=\"noopener\"><sup>(2)<\/sup><\/a><\/p>\n<h4>2. k\u0101 hormons:<\/h4>\n<p>Dopam\u012bns darbojas ar\u012b k\u0101 hormons, kad to asin\u012bs izdala da\u017ei dziedzeri, piem\u0113ram, hipotal\u0101ms. Tam ir noz\u012bme da\u017e\u0101du organisma funkciju regul\u0113\u0161an\u0101, tostarp citu hormonu kontrol\u0113. Svar\u012bga dopam\u012bna hormon\u0101l\u0101 funkcija ir prolakt\u012bna, hormona, kas atbild par piena ra\u017eo\u0161anu, nom\u0101k\u0161ana. T\u0101d\u0113j\u0101di dopam\u012bnam ir svar\u012bga loma reprodukt\u012bvo funkciju, piem\u0113ram, lakt\u0101cijas, regul\u0113\u0161an\u0101. <a href=\"https:\/\/academic.oup.com\/edrv\/article-abstract\/6\/4\/564\/2548821\" target=\"_blank\" rel=\"noopener\"><sup>(3)<\/sup><\/a><\/p>\n<h3>Dopam\u012bna \u0137\u012bmisk\u0101 daba<\/h3>\n<h4>\u0136\u012bmisk\u0101 formula: C\u2088H\u2081\u2081NO\u2082.<\/h4>\n<p>Dopam\u012bns pieder pie kateholam\u012bnu grupas, kam rakstur\u012bgs benzolam\u012bnu gredzens ar div\u0101m hidroksilgrup\u0101m un am\u012bna grupu (-NH\u2082). Dopam\u012bns veidojas no aminosk\u0101bes tiroz\u012bna, kas vispirms tiek p\u0101rv\u0113rsts par L-DOPA un p\u0113c tam par dopam\u012bnu virkn\u0113 fermentat\u012bvo reakciju. \u0160aj\u0101 proces\u0101 ir iesaist\u012bti enz\u012bmi tiroz\u012bna hidroksil\u0101ze un arom\u0101tisk\u0101 L-am\u012bnsk\u0101bes dekarboksil\u0101ze. <a href=\"https:\/\/pubs.acs.org\/doi\/full\/10.1021\/la204831b?casa_token=Ty8VXX1bQj8AAAAA%3AktuRZiEL9F6yyQ4wAu_goi-M2D5L_P8V3XszBA5FyRJcXruCnfCl3xKhUtKCkluM1itLoaFh5nobb6b0\" target=\"_blank\" rel=\"noopener\"><sup>(4)<\/sup><\/a><\/p>\n<h3>Fiziolo\u0123isk\u0101s un biolo\u0123isk\u0101s \u012bpa\u0161\u012bbas<\/h3>\n<h4>neirofiziolo\u0123isk\u0101s funkcijas:<\/h4>\n<p>Dopam\u012bnam ir svar\u012bga loma kust\u012bbu regul\u0113\u0161an\u0101. Nepietiekams dopam\u012bna l\u012bmenis t\u0101dos re\u0123ionos k\u0101 smadze\u0146u baz\u0101lie gangliji ir saist\u012bts ar Parkinsona slim\u012bbu, kas izraisa tr\u012bci, st\u012bvumu un kust\u012bbu pal\u0113nin\u0101\u0161anos. Dopam\u012bnam ir b\u016btiska noz\u012bme smadze\u0146u atalgojuma sist\u0113m\u0101. Tas izdal\u0101s, rea\u0123\u0113jot uz pat\u012bkamiem stimuliem, piem\u0113ram, \u0113dienu vai soci\u0101lo mijiedarb\u012bbu, un pastiprina noteiktu uzved\u012bbu, izraisot apmierin\u0101t\u012bbas vai baudas saj\u016btu. Dopam\u012bns ir iesaist\u012bts m\u0101c\u012b\u0161an\u0101s, atmi\u0146as un l\u0113mumu pie\u0146em\u0161anas procesos, \u012bpa\u0161i saist\u012bb\u0101 ar atl\u012bdz\u012bbu. Tas pal\u012bdz motiv\u0113jo\u0161\u0101s darb\u012bb\u0101s un m\u0101c\u012bb\u0101s, izmantojot pastiprin\u0101jumu. Dopam\u012bns ietekm\u0113 ar\u012b garast\u0101vok\u013ca regul\u0101ciju, un dopam\u012bna signaliz\u0101cijas trauc\u0113jumi ir saist\u012bti ar depresiju un bipol\u0101riem afekt\u012bviem trauc\u0113jumiem, kas var rasties dopam\u012bna sist\u0113mas nel\u012bdzsvarot\u012bbas d\u0113\u013c. <a href=\"\/lv\/Krzymowski,%20T.,%20&amp;%20Stefanczyk-Krzymowska,%20S.%20(2015).%20New%20facts%20and%20the%20concept%20of%20physiological%20regulation%20of%20the%20dopaminergic%20system%20function%20and%20its%20disorders.%20J%20Physiol%20Pharmacol,%2066(3),%20331-341.\/\"><sup>(5)<\/sup><\/a><\/p>\n<h4>Papildu biolo\u0123isk\u0101s lomas:<\/h4>\n<p>Dopam\u012bns ietekm\u0113 ar\u012b sirds un asinsvadu sist\u0113mu, kur, mijiedarbojoties ar receptoriem organism\u0101, tas var ietekm\u0113t sirdsdarb\u012bbu un asinsspiedienu. Tom\u0113r \u0161\u012b darb\u012bba ir sekund\u0101ra sal\u012bdzin\u0101jum\u0101 ar t\u0101 lomu smadzen\u0113s. <a href=\"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/5042\" target=\"_blank\" rel=\"noopener\"><sup>(6<\/sup><\/a>) Tam ir noz\u012bme gremo\u0161anas sist\u0113m\u0101, jo tas ietekm\u0113 motoriku un apet\u012btes regul\u0113\u0161anu, k\u0101 ar\u012b refleksus zarn\u0101s. <a href=\"https:\/\/link.springer.com\/article\/10.1007\/s001340051279\" target=\"_blank\" rel=\"noopener\"><sup>(7)<\/sup><\/a><\/p>\n<p>&nbsp;<\/p>\n<h3>Darb\u012bbas meh\u0101nisms<\/h3>\n<p>Dopam\u012bna darb\u012bbas meh\u0101nisms ietver gan neirotransmitera funkciju smadzen\u0113s, gan hormona funkciju perif\u0113raj\u0101 sist\u0113m\u0101. Tas iedarbojas galvenok\u0101rt, saistoties ar dopam\u012bna receptoriem, kas atrodas centr\u0101laj\u0101 nervu sist\u0113m\u0101 (CNS) un da\u017e\u0101dos perif\u0113ros audos. \u0160ie receptori ir da\u013ca no liel\u0101kas G prote\u012bnu saist\u012bto receptoru (GPCR) saimes, kas, aktiviz\u0113joties dopam\u012bnam, medi\u0113 intracelul\u0101r\u0101s signaliz\u0101cijas ce\u013cus. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959438818302587?casa_token=HsC5mNyRRrgAAAAA:vETxwdrB3Cw9AmPPm-4OlLxAXcnNHvbdhRkOuvwGJyvZvrMCGR5e66MGWnkc16JV9SsbAlc_vaI\" target=\"_blank\" rel=\"noopener\"><sup>(8)<\/sup><\/a><\/p>\n<h3>Dopam\u012bna receptori<\/h3>\n<p>Dopam\u012bns iedarbojas uz pieciem da\u017e\u0101diem receptoru apak\u0161tipiem - D1, D2, D3, D4 un D5. \u0160os receptorus var iedal\u012bt div\u0101s grup\u0101s, pamatojoties uz to darb\u012bbu \u0161\u016bn\u0101s:<\/p>\n<ol>\n<li>\n<h4>D1 l\u012bdz\u012bgi receptori (D1 un D5):<\/h4>\n<p>\u0160ie receptori galvenok\u0101rt ir uzbudino\u0161i. Kad dopam\u012bns saist\u0101s ar D1 tipa receptoriem, tas aktiviz\u0113 enz\u012bmu adenilcikl\u0101zi, kas palielina ciklisk\u0101 AMP (cAMP) l\u012bmeni \u0161\u016bn\u0101. \u0160is cAMP pieaugums aktiviz\u0113 prote\u012bnkin\u0101zi A (PKA), kas savuk\u0101rt modul\u0113 da\u017e\u0101dus \u0161\u016bnu procesus, piem\u0113ram, neironu uzbudin\u0101m\u012bbu, sinaptisko plastiskumu un g\u0113nu ekspresiju. Smadzen\u0113s \u0161ie receptori ir iesaist\u012bti t\u0101dos procesos k\u0101 m\u0101c\u012b\u0161an\u0101s, atmi\u0146as un garast\u0101vok\u013ca regul\u0113\u0161ana. <a href=\"\/lv\/Beaulieu,%20J.%20M.,%20Espinoza,%20S.,%20&amp;%20Gainetdinov,%20R.%20R.%20(2015).%20Dopamine%20receptors\u2013IUPHAR%20R%20eview%2013.%20British%20journal%20of%20pharmacology,%20172(1),%201-23.\/\"><sup>(9)<\/sup><\/a><\/li>\n<li>\n<h4><strong>D2 l\u012bdz\u012bgi receptori (D2, D3, D4):<\/strong><\/h4>\n<p>\u0160iem receptoriem parasti ir nom\u0101co\u0161a iedarb\u012bba. Dopam\u012bna saist\u012b\u0161an\u0101s ar D2 tipa receptoriem inhib\u0113 adenilcikl\u0101zes aktivit\u0101ti, izraisot cAMP l\u012bme\u0146a samazin\u0101\u0161anos. \u0160is cAMP samazin\u0101jums samazina PKA aktivit\u0101ti, ietekm\u0113jot jonu kan\u0101lu darb\u012bbu un \u0161\u016bnu uzbudin\u0101m\u012bbu. D2 l\u012bdz\u012bgie receptori ir \u012bpa\u0161i svar\u012bgi motorisk\u0101s kontroles, atalgojuma un kognit\u012bvo funkciju regul\u0113\u0161an\u0101. D2 receptoru signaliz\u0101cijas trauc\u0113jumi ir saist\u012bti ar t\u0101diem trauc\u0113jumiem k\u0101 Parkinsona slim\u012bba un \u0161izofr\u0113nija. <a href=\"\/lv\/Beaulieu,%20J.%20M.,%20Espinoza,%20S.,%20&amp;%20Gainetdinov,%20R.%20R.%20(2015).%20Dopamine%20receptors\u2013IUPHAR%20R%20eview%2013.%20British%20journal%20of%20pharmacology,%20172(1),%201-23.\/\"><sup>(9)<\/sup><\/a><\/li>\n<\/ol>\n<h3>Dopam\u012bns centr\u0101laj\u0101 nervu sist\u0113m\u0101<\/h3>\n<p>Dopam\u012bnam ir b\u016btiska ietekme uz vair\u0101kiem svar\u012bgiem smadze\u0146u ce\u013ciem. \u0160ie ce\u013ci ietver mezolimbiskos, mezokortik\u0101los un nigrostriat\u0101los ce\u013cus, no kuriem katrs veicina da\u017e\u0101dus uzved\u012bbas un funkciju aspektus.<\/p>\n<ul>\n<li>\n<h4>Mezolimbiskais ce\u013c\u0161:<\/h4>\n<p>Dopam\u012bnam, kas izdal\u0101s \u0161aj\u0101 ce\u013c\u0101, ir galven\u0101 loma atl\u012bdz\u012bbas sist\u0113m\u0101. Tas ir iesaist\u012bts uzved\u012bbas pastiprin\u0101\u0161an\u0101, sniedzot baudas vai apmierin\u0101juma saj\u016btu, jo \u012bpa\u0161i rea\u0123\u0113jot uz t\u0101diem atalgojo\u0161iem stimuliem k\u0101 \u0113diens, sekss vai soci\u0101l\u0101 saskarsme. \u0160is ce\u013c\u0161 ir saist\u012bts ar atkar\u012bbu, jo narkotikas var p\u0101r\u0146emt dopam\u012bna signaliz\u0113\u0161anu, t\u0101d\u0113j\u0101di pastiprinot uzved\u012bbu, kas veicina narkotiku mekl\u0113\u0161anu. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0149763406001102?casa_token=wNW7P2AVPG4AAAAA:EFGU-aDDUBLDT1uTuGzTM-9E3bhr7qqqf31ocW3L8cBPUjO4aSZ4IVFz5JdArfYGl-KOyvKaWh4\" target=\"_blank\" rel=\"noopener\"><sup>(10)<\/sup><\/a><\/li>\n<li>\n<h4>Nigrostriat\u0101lais ce\u013c\u0161:<\/h4>\n<p>Dopam\u012bnam \u0161aj\u0101 ce\u013c\u0101 ir b\u016btiska noz\u012bme kust\u012bbu kontrol\u0113. Tas veidojas melnaj\u0101 viel\u0101 un tiek p\u0101rraid\u012bts uz striatum. Dopam\u012bns pal\u012bdz modul\u0113t motorisk\u0101s \u0137\u0113des, kas saist\u012btas ar smalkaj\u0101m kust\u012bb\u0101m un koordin\u0101ciju. Dopam\u012bnu ra\u017eojo\u0161o neironu zudums \u0161aj\u0101 ce\u013c\u0101 izraisa Parkinsona slim\u012bbu, kuras laik\u0101 rodas t\u0101di motoriski simptomi k\u0101 tr\u012bce, st\u012bvums un bradikin\u0113zija (kust\u012bbu l\u0113nums). <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0149763406001102?casa_token=wNW7P2AVPG4AAAAA:EFGU-aDDUBLDT1uTuGzTM-9E3bhr7qqqf31ocW3L8cBPUjO4aSZ4IVFz5JdArfYGl-KOyvKaWh4\" target=\"_blank\" rel=\"noopener\"><sup>(10)<\/sup><\/a><\/li>\n<li>\n<h4><strong>Mezokortik\u0101lais ce\u013c\u0161: <\/strong><\/h4>\n<p>Dopam\u012bns mezokortik\u0101laj\u0101 ce\u013c\u0101 ietekm\u0113 kognit\u012bv\u0101s funkcijas, emocion\u0101lo regul\u0101ciju un izpildfunkcijas. Tas ir iesaist\u012bts t\u0101dos procesos k\u0101 l\u0113mumu pie\u0146em\u0161ana, uzman\u012bba un garast\u0101vok\u013ca regul\u0113\u0161ana. \u0160\u012b ce\u013ca disfunkcija ir saist\u012bta ar \u0161izofr\u0113niju un citiem garast\u0101vok\u013ca trauc\u0113jumiem, kad ir trauc\u0113ta kognit\u012bv\u0101 un emocion\u0101l\u0101 regul\u0101cija. <a href=\"https:\/\/europepmc.org\/article\/med\/17886476\" target=\"_blank\" rel=\"noopener\"><sup>(11)<\/sup><\/a><\/li>\n<\/ul>\n<h3>Dopam\u012bns perif\u0113raj\u0101 sist\u0113m\u0101<\/h3>\n<p>Papildus centr\u0101lajai darb\u012bbai dopam\u012bnam organism\u0101 ir ar\u012b hormon\u0101la noz\u012bme. Perif\u0113riskaj\u0101 sist\u0113m\u0101 dopam\u012bns galvenok\u0101rt darbojas k\u0101 vazodilatators. Tas iedarbojas uz asinsvadu glud\u0101s muskulat\u016bras atsl\u0101bin\u0101\u0161anu, k\u0101 rezult\u0101t\u0101 samazin\u0101s asinsspiediens. \u0160\u012b ietekme ir \u012bpa\u0161i svar\u012bga nieru darb\u012bb\u0101, kur dopam\u012bns pal\u012bdz regul\u0113t nieru asins pl\u016bsmu, n\u0101trija izdal\u012b\u0161anos un visp\u0101r\u0113jo nieru darb\u012bbu. Dopam\u012bna loma sirds un asinsvadu sist\u0113m\u0101 ir sare\u017e\u0123\u012bt\u0101ka, jo t\u0101 iedarb\u012bba var at\u0161\u0137irties atkar\u012bb\u0101 no dopam\u012bna receptoru koncentr\u0101cijas un konkr\u0113t\u0101 tipa. <a href=\"https:\/\/www.researchgate.net\/profile\/Seyed-Khosrow-Tayebati\/publication\/11031049_The_peripheral_dopaminergic_system_morphological_analysis_functional_and_clinical_applications\/links\/55edc0cb08aedecb68fbaf1f\/The-peripheral-dopaminergic-system-morphological-analysis-functional-and-clinical-applications.pdf\" target=\"_blank\" rel=\"noopener\"><sup>(12)<\/sup><\/a><\/p>\n<p>&nbsp;<\/p>\n<h3>Dopam\u012bns un t\u0101 ietekme uz citiem neiromediatoriem<\/h3>\n<p>Dopam\u012bns, lai gan tas ir \u013coti svar\u012bgs smadze\u0146u darb\u012bbai, nav vien\u012bgais neirotransmiters, kas iesaist\u012bts garast\u0101vok\u013ca regul\u0113\u0161an\u0101. Tas mijiedarbojas ar vair\u0101kiem citiem neiromediatoriem, piem\u0113ram, seroton\u012bnu, norepinefr\u012bnu, glutam\u0101tu un GABA, un kompleksi ietekm\u0113 garast\u0101vokli, uzved\u012bbu un kognit\u012bv\u0101s funkcijas. Katram no \u0161iem neiromediatoriem ir sava loma, ta\u010du to mijiedarb\u012bba, \u012bpa\u0161i noteikt\u0101s kombin\u0101cij\u0101s, var b\u016btiski ietekm\u0113t m\u016bsu pa\u0161saj\u016btu un uzved\u012bbu.<\/p>\n<p>Dopam\u012bna mijiedarb\u012bba ar citiem neiromediatoriem tie\u0161i ietekm\u0113 garast\u0101vokli, emocion\u0101lo st\u0101vokli un uzved\u012bbu. \u0160eit ir da\u017ei piem\u0113ri, k\u0101 dopam\u012bns un t\u0101 kombin\u0101cijas ietekm\u0113 garast\u0101vokli:<\/p>\n<h3>Dopam\u012bna un seroton\u012bna kombin\u0101cija:<\/h3>\n<h4>L\u012bdzsvarots dopam\u012bna un seroton\u012bna l\u012bmenis:<\/h4>\n<p>Dopam\u012bna un seroton\u012bna harmonija veicina pozit\u012bvu garast\u0101vokli, paaugstin\u0101tu motiv\u0101ciju un emocion\u0101lo labsaj\u016btu. \u0160is l\u012bdzsvars var palielin\u0101t baudas saj\u016btu, neradot p\u0101rlieku uzbudin\u0101jumu vai trauksmi.<\/p>\n<h4>Dopam\u012bna defic\u012bts ar augstu seroton\u012bna l\u012bmeni:<\/h4>\n<p>Zems dopam\u012bna l\u012bmenis kombin\u0101cij\u0101 ar augstu seroton\u012bna l\u012bmeni var izrais\u012bt emocion\u0101lu stabilit\u0101ti, bet motiv\u0101cijas tr\u016bkumu un zemu ener\u0123ijas l\u012bmeni. Tas var veicin\u0101t apmierin\u0101t\u012bbu, bet motiv\u0101cijas tr\u016bkumu vai vienaldz\u012bbu. <a href=\"https:\/\/www.pnas.org\/doi\/abs\/10.1073\/pnas.1201547109\" target=\"_blank\" rel=\"noopener\"><sup>(13)<\/sup><\/a><\/p>\n<h3>Dopam\u012bna un noradrenal\u012bna kombin\u0101cija:<\/h3>\n<h4>Dopam\u012bna un norepinefr\u012bna l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s:<\/h4>\n<p>Ja abu neiromediatoru l\u012bmenis ir paaugstin\u0101ts, cilv\u0113ks var justies \u013coti motiv\u0113ts, ener\u0123isks un koncentr\u0113ts, ar paaugstin\u0101tu motiv\u0101cijas un uzman\u012bbas l\u012bmeni. \u0160\u012b kombin\u0101cija bie\u017ei vien izpau\u017eas k\u0101 liel\u0101ka produktivit\u0101te un koncentr\u0113\u0161an\u0101s.<\/p>\n<h4>Dopam\u012bna p\u0101rpalikums kombin\u0101cij\u0101 ar noradrenal\u012bnu:<\/h4>\n<p>Dopam\u012bna p\u0101rpalikums kombin\u0101cij\u0101 ar p\u0101r\u0101k lielu noradrenal\u012bna daudzumu var izrais\u012bt paaugstin\u0101tu trauksmi, impulsivit\u0101ti vai maniak\u0101lu uzved\u012bbu, jo smadzenes s\u0101k darboties hiperakt\u012bv\u0101 un modr\u012bbas re\u017e\u012bm\u0101. <a href=\"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/481645\" target=\"_blank\" rel=\"noopener\"><sup>(14)<\/sup><\/a><\/p>\n<h3>Dopam\u012bna un glutam\u0101ta kombin\u0101cija:<\/h3>\n<h4>Dopam\u012bna un glutam\u0101ta sinhroniz\u0101cija:<\/h4>\n<p>\u0160ie neirotransmiteri darbojas kop\u0101, lai atbalst\u012btu atmi\u0146u un m\u0101c\u012b\u0161anos un uztur\u0113tu motiv\u0101ciju. Vesel\u012bgs l\u012bdzsvars veicina efekt\u012bvu m\u0101c\u012b\u0161anos un produkt\u012bvu uzved\u012bbu, jo dopam\u012bns uzlabo motiv\u0101ciju, bet glutam\u0101ts veicina kognit\u012bvos procesus.<\/p>\n<h4>Dopam\u012bna defic\u012bts ar glutam\u0101ta disfunkciju<strong>:<\/strong><\/h4>\n<p>Ja dopam\u012bna l\u012bmenis ir zems un glutam\u0101ta l\u012bmenis ir trauc\u0113ts, var rasties kognit\u012bvi trauc\u0113jumi, atmi\u0146as probl\u0113mas vai gr\u016bt\u012bbas koncentr\u0113ties. Tas var veicin\u0101t uzman\u012bbas defic\u012bta trauc\u0113jumu un pat depresijas simptomus. <a href=\"https:\/\/www.thieme-connect.com\/products\/ejournals\/html\/10.1055\/s-0031-1273707\" target=\"_blank\" rel=\"noopener\"><sup>(15)<\/sup><\/a><\/p>\n<h3>Dopam\u012bna un GABA kombin\u0101cija:<\/h3>\n<h4>GABA regul\u0113ts dopam\u012bns:<\/h4>\n<p>Dopam\u012bnam un GABA j\u0101darbojas tand\u0113m\u0101, lai veicin\u0101tu darb\u012bbas un relaks\u0101cijas l\u012bdzsvaru. Vesel\u012bga abu \u0161o vielu kombin\u0101cija rada stabilu emocion\u0101lo st\u0101vokli, kur\u0101 cilv\u0113ki ir motiv\u0113ti, bet nav p\u0101r\u0146emti ar trauksmi vai hiperaktivit\u0101ti.<\/p>\n<h3>Augsts dopam\u012bna l\u012bmenis un zems GABA l\u012bmenis:<\/h3>\n<p>\u0160\u012b nel\u012bdzsvarot\u012bba var izrais\u012bt impuls\u012bvu uzved\u012bbu, aizkaitin\u0101m\u012bbu, trauksmi un p\u0101rm\u0113r\u012bgu stimul\u0101ciju. Un otr\u0101di, dopam\u012bna tr\u016bkums kop\u0101 ar augstu GABA l\u012bmeni var izrais\u012bt vienm\u0113r\u012bgu, maz ener\u0123isku garast\u0101vokli, kas bie\u017ei vien ir saist\u012bts ar depresiju. <a href=\"https:\/\/psycnet.apa.org\/fulltext\/2014-56250-020.html?source=post_page---------------------------\" target=\"_blank\" rel=\"noopener\"><sup>(16)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns un kortizols<\/h3>\n<p>Kortizols ir galvenais stresa hormons, ko virsnieru dziedzeri izdala, rea\u0123\u0113jot uz stresu. Dopam\u012bna un kortizola mijiedarb\u012bba ir sare\u017e\u0123\u012bta. Dopam\u012bns var veicin\u0101t motiv\u0101ciju un atalgojuma mekl\u0113\u0161anu, bet kortizols paaugstin\u0101ta stresa apst\u0101k\u013cos var nom\u0101kt dopam\u012bna darb\u012bbu. Hroniska stresa rezult\u0101t\u0101 var samazin\u0101ties dopam\u012bna receptoru jut\u012bba, t\u0101d\u0113j\u0101di cilv\u0113kiem ir gr\u016bti izjust baudu un motiv\u0101ciju. Piem\u0113ram, hroniska stresa vai trauksmes gad\u012bjum\u0101 paaugstin\u0101ta kortizola l\u012bme\u0146a un pazemin\u0101tas dopam\u012bna funkcijas mijiedarb\u012bba var veicin\u0101t izdeg\u0161anas saj\u016btu, motiv\u0101cijas tr\u016bkumu un depresiju. <a href=\"https:\/\/academic.oup.com\/ejendo\/article-abstract\/122\/1\/29\/6771151\" target=\"_blank\" rel=\"noopener\"><sup>(17)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns un oksitoc\u012bns<\/h3>\n<p>Oksitoc\u012bnam, ko d\u0113v\u0113 par \"saiknes hormonu\", ir b\u016btiska noz\u012bme soci\u0101l\u0101s saiknes, uztic\u0113\u0161an\u0101s un emocion\u0101l\u0101s regul\u0113\u0161anas procesos. Dopam\u012bns un oksitoc\u012bns var stiprin\u0101t soci\u0101l\u0101s saites un m\u012blest\u012bbas un pie\u0137er\u0161an\u0101s saj\u016btu. Dopam\u012bns palielina soci\u0101l\u0101s mijiedarb\u012bbas prieku un atalgojumu, savuk\u0101rt oksitoc\u012bns veicina saikni un emp\u0101tiju. Dopam\u012bna (kas saist\u012bts ar baudu un atl\u012bdz\u012bbu) un oksitoc\u012bna (kas saist\u012bts ar saikni un uztic\u0113\u0161anos) kombin\u0101cija var pastiprin\u0101t emocion\u0101l\u0101s saites un pie\u0137er\u0161an\u0101s saj\u016btas. <a href=\"https:\/\/www.mdpi.com\/2227-9059\/12\/11\/2440\" target=\"_blank\" rel=\"noopener\"><sup>(18)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns un endorf\u012bni<\/h3>\n<p>Endorf\u012bni ir smadze\u0146u dabiskie prets\u0101pju l\u012bdzek\u013ci, un tie ir saist\u012bti ar eiforijas un labsaj\u016btas saj\u016btu, kas bie\u017ei vien izdal\u0101s p\u0113c fiziskas slodzes vai pat\u012bkamu darb\u012bbu rezult\u0101t\u0101. Endorf\u012bni un dopam\u012bns darbojas kop\u0101 smadze\u0146u atl\u012bdz\u012bbas un baudas sist\u0113m\u0101. Dopam\u012bns ir saist\u012bts ar baudas gaid\u012b\u0161anu, savuk\u0101rt endorf\u012bni izdal\u0101s, kad bauda tiek izjusta. Kop\u0101 tie veicina laimes un apmierin\u0101t\u012bbas saj\u016btu. Treni\u0146u izrais\u012bta eiforija (bie\u017ei d\u0113v\u0113ta par \"skr\u0113j\u0113ja uzmundrin\u0101jumu\") ir gan dopam\u012bna, gan endorf\u012bnu izdal\u012b\u0161an\u0101s rezult\u0101ts, kas palielina motiv\u0101ciju un pozit\u012bvi pastiprina aktivit\u0101ti. <a href=\"https:\/\/pdfs.semanticscholar.org\/4fb3\/a88ff070092e0e0f0e3a8cd00c26be527f2f.pdf\" target=\"_blank\" rel=\"noopener\"><sup>(19)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns un acetilhol\u012bns<\/h3>\n<p>Acetilhol\u012bns ir \u013coti svar\u012bgs atmi\u0146as, m\u0101c\u012b\u0161an\u0101s un musku\u013cu kontrolei. Tam ir liela noz\u012bme smadze\u0146u sp\u0113j\u0101 apstr\u0101d\u0101t jaunu inform\u0101ciju un piev\u0113rst uzman\u012bbu. Dopam\u012bna un acetilhol\u012bna mijiedarb\u012bba smadzen\u0113s var ietekm\u0113t kognit\u012bv\u0101s funkcijas. Piem\u0113ram, Parkinsona slim\u012bbas gad\u012bjum\u0101 ir dopam\u012bna defic\u012bts, kas izraisa kust\u012bbu un kognit\u012bv\u0101s funkcijas trauc\u0113jumus. Viena no Parkinsona slim\u012bbas \u0101rst\u0113\u0161anas metod\u0113m ir v\u0113rsta uz dopam\u012bna un acetilhol\u012bna l\u012bme\u0146a l\u012bdzsvaro\u0161anu, lai uzlabotu motorisk\u0101s funkcijas. T\u0101du slim\u012bbu gad\u012bjum\u0101 k\u0101 Parkinsona slim\u012bba z\u0101les, kas palielina acetilhol\u012bna aktivit\u0101ti (piem\u0113ram, antihol\u012bner\u0123iskie l\u012bdzek\u013ci), var pal\u012bdz\u0113t l\u012bdzsvarot dopam\u012bna defic\u012btu un samazin\u0101t tr\u012bci vai st\u012bvumu. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/0006899391903848\" target=\"_blank\" rel=\"noopener\"><sup>(20)<\/sup><\/a><\/p>\n<h2>Garast\u0101vok\u013ca sv\u0101rst\u012bbas ar dopam\u012bna l\u012bmeni<\/h2>\n<p>Garast\u0101vok\u013ca sv\u0101rst\u012bbas bie\u017ei vien ir cie\u0161i saist\u012btas ar neiromediatoru, piem\u0113ram, dopam\u012bna, l\u012bme\u0146a izmai\u0146\u0101m, kam ir b\u016btiska noz\u012bme emociju, motiv\u0101cijas un atl\u012bdz\u012bbas apstr\u0101des regul\u0113\u0161an\u0101 smadzen\u0113s. Ja dopam\u012bna l\u012bmenis ir l\u012bdzsvarots, cilv\u0113ki parasti izj\u016bt stabilu garast\u0101vokli, motiv\u0101ciju un sp\u0113ju izjust baudu. Tom\u0113r dopam\u012bna l\u012bme\u0146a sv\u0101rst\u012bbas var izrais\u012bt b\u016btiskas garast\u0101vok\u013ca izmai\u0146as. \u0160eit ir apkopota zin\u0101tnisk\u0101 inform\u0101cija par dopam\u012bna l\u012bme\u0146a ietekmi uz garast\u0101vok\u013ca sv\u0101rst\u012bb\u0101m:<\/p>\n<h3>Dopam\u012bns un atalgojuma sist\u0113ma<\/h3>\n<p>Dopam\u012bns ir galven\u0101 smadze\u0146u atalgojuma sist\u0113mas sast\u0101vda\u013ca, kas ir atbild\u012bga par pat\u012bkamas pieredzes apstr\u0101di un atalgojumu veicino\u0161as uzved\u012bbas pastiprin\u0101\u0161anu. Dopam\u012bna izdal\u012b\u0161an\u0101s izraisa baudas un apmierin\u0101t\u012bbas saj\u016btu, kas bie\u017ei rodas p\u0113c t\u0101d\u0101m darb\u012bb\u0101m k\u0101 \u0113\u0161ana, socializ\u0113\u0161an\u0101s vai m\u0113r\u0137u sasnieg\u0161ana. Zems dopam\u012bna l\u012bmenis var kav\u0113t baudas vai motiv\u0101cijas izj\u016btu, izraisot ap\u0101tijas, anhedonijas (nesp\u0113jas izjust baudu) un zema ener\u0123ijas l\u012bme\u0146a saj\u016btu. No otras puses, augsts dopam\u012bna l\u012bmenis var izrais\u012bt liel\u0101ku baudu un uzbudin\u0101jumu, bet, ja p\u0101r\u0101k \u0101tri izdal\u0101s p\u0101r\u0101k daudz dopam\u012bna, tas var izrais\u012bt p\u0101rm\u0113r\u012bgu stimul\u0101ciju, izraisot trauksmi, aizkaitin\u0101m\u012bbu un pat impulsivit\u0101ti. <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/j.1600-0447.2005.00540.x?casa_token=rG5BTN_AltwAAAAA%3A5VzH55lRpmqof2oMACNkGqtr4P_bTPywY8HzKUFtr_y0oArhUt5KY_LpBhxLosCp2bxaB9x51ZtNtTdu\" target=\"_blank\" rel=\"noopener\"><sup>(21)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns un \"baudas palielin\u0101\u0161anas\" \u0137\u0113de<\/h3>\n<p>Dopam\u012bnam ir galven\u0101 loma mezolimbiskaj\u0101 dopam\u012bner\u0123iskaj\u0101 ce\u013c\u0101, kas ir smadze\u0146u \"atl\u012bdz\u012bbas centrs\". \u0160is ce\u013c\u0161 ietver t\u0101das svar\u012bgas strukt\u016bras k\u0101 nucleus accumbens, kas pal\u012bdz regul\u0113t baudas saj\u016btu, un prefront\u0101lo garozu, kas ir iesaist\u012bta l\u0113mumu pie\u0146em\u0161an\u0101, pl\u0101no\u0161an\u0101 un m\u0113r\u0137u izvirz\u012b\u0161an\u0101. Kad cilv\u0113ks piedz\u012bvo kaut ko pat\u012bkamu (piem\u0113ram, \u0113dot vai sa\u0146emot komplimentu), \u0161aj\u0101s zon\u0101s izdal\u0101s dopam\u012bns, kas pastiprina uzved\u012bbu. Dopam\u012bna izdal\u012b\u0161an\u0101s pal\u012bdz nostiprin\u0101t saikni starp darb\u012bbu un pozit\u012bvo pieredzi, motiv\u0113jot indiv\u012bdu mekl\u0113t l\u012bdz\u012bgu atl\u012bdz\u012bbu n\u0101kotn\u0113. Ja dopam\u012bna l\u012bmenis \u0161aj\u0101 ce\u013c\u0101 ir zems vai trauc\u0113ts, atalgojuma pastiprin\u0101\u0161anas sist\u0113ma ir trauc\u0113ta, k\u0101 rezult\u0101t\u0101 rodas gr\u016bt\u012bbas izjust prieku vai motiv\u0101ciju. Un otr\u0101di, p\u0101r\u0101k augsts dopam\u012bna l\u012bmenis var izrais\u012bt p\u0101rm\u0113r\u012bgu tieksmi p\u0113c atl\u012bdz\u012bbas, bie\u017ei vien ne\u0146emot v\u0113r\u0101 sekas. <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/j.1600-0447.2005.00540.x?casa_token=rG5BTN_AltwAAAAA%3A5VzH55lRpmqof2oMACNkGqtr4P_bTPywY8HzKUFtr_y0oArhUt5KY_LpBhxLosCp2bxaB9x51ZtNtTdu\" target=\"_blank\" rel=\"noopener\"><sup>(21)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns un stresa reakcija<\/h3>\n<p>Hronisks stress var b\u016btiski ietekm\u0113t dopam\u012bna l\u012bmeni, izraisot izmai\u0146as garast\u0101vok\u013ca regul\u0101cij\u0101. Augsts kortizola (stresa hormona) l\u012bmenis var kav\u0113t dopam\u012bna sp\u0113ju pareizi darboties. Hronisks stress vai ilgsto\u0161i augsta kortizola l\u012bme\u0146a periodi var desensibiliz\u0113t dopam\u012bna receptorus, apgr\u016btinot smadze\u0146u reakciju uz atl\u012bdz\u012bbas sign\u0101liem. Tas var izrais\u012bt dopam\u012bna defic\u012btu, kas veicina t\u0101dus simptomus k\u0101 nogurums, skumjas un motiv\u0101cijas tr\u016bkums. Turpret\u012b ak\u016bts stress vai \u012bslaic\u012bgs dopam\u012bna l\u012bme\u0146a pieaugums (nov\u0113rojams paaugstin\u0101ta uztraukuma vai izaicin\u0101jumu br\u012b\u017eos) var izrais\u012bt \u012bslaic\u012bgu garast\u0101vok\u013ca un motiv\u0101cijas uzlabo\u0161anos. Tom\u0113r, ja \u0161\u0101ds st\u0101voklis saglab\u0101jas bez atbilsto\u0161as relaks\u0101cijas vai atjauno\u0161an\u0101s, tas var novest pie izdeg\u0161anas vai emocion\u0101l\u0101 izs\u012bkuma. <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/j.1600-0447.2005.00540.x?casa_token=rG5BTN_AltwAAAAA%3A5VzH55lRpmqof2oMACNkGqtr4P_bTPywY8HzKUFtr_y0oArhUt5KY_LpBhxLosCp2bxaB9x51ZtNtTdu\" target=\"_blank\" rel=\"noopener\"><sup>(21)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns un motiv\u0101cijas sist\u0113ma<\/h3>\n<p>Dopam\u012bns ir iesaist\u012bts ar\u012b smadze\u0146u motiv\u0101cijas sist\u0113m\u0101, \u012bpa\u0161i prefront\u0101laj\u0101 garoz\u0101 un striatum\u0101. Motiv\u0101cija ietver ne tikai atl\u012bdz\u012bbas gaid\u012b\u0161anu, bet ar\u012b tieksmi sasniegt m\u0113r\u0137us. Ja dopam\u012bna l\u012bmenis ir augsts, tas palielina smadze\u0146u tieksmi sasniegt m\u0113r\u0137us, uz\u0146emties iniciat\u012bvu un iesaist\u012bties aktivit\u0101t\u0113s. \u0160\u012b motiv\u0101cijas saj\u016bta var rad\u012bt pozit\u012bvu garast\u0101vokli, jo cilv\u0113ki j\u016btas ener\u0123iski un m\u0113r\u0137tiec\u012bgi. Ja dopam\u012bna l\u012bmenis ir zems, indiv\u012bdiem var b\u016bt gr\u016bti uzs\u0101kt darb\u012bbu, vi\u0146i var justies nemotiv\u0113ti un piedz\u012bvot t\u0101dus noska\u0146ojuma st\u0101vok\u013cus k\u0101 ap\u0101tija vai vienaldz\u012bba. Tas bie\u017ei nov\u0113rojams t\u0101dos st\u0101vok\u013cos k\u0101 depresija vai trauksme, kad pat vienk\u0101r\u0161i uzdevumi var \u0161\u0137ist nep\u0101rvarami un sare\u017e\u0123\u012bti. <a href=\"https:\/\/psycnet.apa.org\/record\/2009-13385-013\" target=\"_blank\" rel=\"noopener\"><sup>(22)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns un \"hedonisma treadmill\"<\/h3>\n<p>Hedonisk\u0101 treadmill koncepcija liecina, ka cilv\u0113ki \u0101tri piel\u0101gojas jaunam baudas vai apmierin\u0101juma l\u012bmenim, kas p\u0113c pozit\u012bvas vai negat\u012bvas pieredzes noved pie atgrie\u0161an\u0101s pie s\u0101kotn\u0113j\u0101 laimes l\u012bme\u0146a. \u0160o piel\u0101go\u0161anos da\u013c\u0113ji veicina dopam\u012bns. P\u0113c pozit\u012bvas pieredzes vai atl\u012bdz\u012bbas dopam\u012bna l\u012bmenis paaugstin\u0101s, bet sal\u012bdzino\u0161i \u0101tri atgrie\u017eas s\u0101kotn\u0113j\u0101 l\u012bmen\u012b. Rezult\u0101t\u0101 cilv\u0113ki var past\u0101v\u012bgi mekl\u0113t jaunus prieka vai atl\u012bdz\u012bbas avotus, lai saglab\u0101tu paaugstin\u0101tu dopam\u012bna l\u012bmeni un izvair\u012btos no neapmierin\u0101t\u012bbas saj\u016btas. Tas var izrais\u012bt garast\u0101vok\u013ca sv\u0101rst\u012bbu ciklu, jo cilv\u0113ki dzenas p\u0113c n\u0101kam\u0101 \"k\u0101puma\" (dopam\u012bna izdal\u012b\u0161an\u0101s), bet nekad piln\u012bb\u0101 neuztur pozit\u012bvu garast\u0101vokli. <a href=\"https:\/\/search.proquest.com\/openview\/8b15ad92068863b671a39a53f08793cc\/1.pdf?pq-origsite=gscholar&amp;cbl=35529\" target=\"_blank\" rel=\"noopener\"><sup>(23)<\/sup><\/a><\/p>\n<h3>Dopam\u012bns un miegs<\/h3>\n<p>Dopam\u012bna l\u012bmeni ietekm\u0113 organisma diennakts ritmi, kas regul\u0113 miega un nomoda ciklus. Miega tr\u016bkums var samazin\u0101t dopam\u012bna receptoru jut\u012bbu, t\u0101p\u0113c n\u0101kamaj\u0101 dien\u0101 ir gr\u016bti justies motiv\u0113tam vai pozit\u012bvi noska\u0146otam. Tas var izrais\u012bt garast\u0101vok\u013ca trauc\u0113jumus, piem\u0113ram, aizkaitin\u0101m\u012bbu vai pazemin\u0101tu garast\u0101vokli. No otras puses, pietiekama atp\u016bta un atjauno\u0161an\u0101s var pal\u012bdz\u0113t uztur\u0113t norm\u0101lu dopam\u012bna funkciju, stabiliz\u0113jot garast\u0101vokli un palielinot emocion\u0101lo notur\u012bbu. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168010217300573?casa_token=NjQmjevEnfYAAAAA:nWKc9O-T_1QXoYgFmq9dBtOUB6_1qVgQbcGhcN1RGuKZKV-ZOYT6rPwA6nvnsBMxS-dLm_ELCFY\" target=\"_blank\" rel=\"noopener\"><sup>(24)<\/sup><\/a><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Dopam\u012bna receptoru stimul\u0101cija, lai modul\u0113tu dopam\u012bner\u0123isko iedarb\u012bbu<\/strong><\/h2>\n<p>Dopam\u012bns ir galvenais neiromediators, kas ietekm\u0113 da\u017e\u0101das smadze\u0146u funkcijas, piem\u0113ram, kust\u012bbas, garast\u0101vokli, atl\u012bdz\u012bbas apstr\u0101di un kognit\u012bv\u0101s funkcijas. Dopam\u012bna receptoru aktiviz\u0101cija da\u017e\u0101dos smadze\u0146u re\u0123ionos izraisa da\u017e\u0101das fiziolo\u0123iskas un uzved\u012bbas reakcijas. \u0100r\u0113jie un iek\u0161\u0113jie faktori var modul\u0113t \u0161o receptoru aktivit\u0101ti, izraisot dopam\u012bner\u0123isk\u0101s iedarb\u012bbas pastiprin\u0101\u0161anos vai pav\u0101jin\u0101\u0161anos.<\/p>\n<h3><strong>Dopam\u012bner\u0123isk\u0101 reakcija un ietekme<\/strong><\/h3>\n<p>Dopam\u012bner\u0123isk\u0101 reakcija ir uzved\u012bbas un smadze\u0146u darb\u012bbas izmai\u0146as, kas rodas p\u0113c dopam\u012bna receptoru aktiviz\u0113\u0161an\u0101s. \u0160\u012bs reakcijas ir b\u016btiskas daudz\u0101m funkcij\u0101m, tostarp:<\/p>\n<h4>Motora vad\u012bba:<\/h4>\n<p>Dopam\u012bns ir \u013coti iesaist\u012bts kust\u012bbu regul\u0113\u0161an\u0101, jo \u012bpa\u0161i t\u0101d\u0101s zon\u0101s k\u0101 striatum. \u0160\u012bs sist\u0113mas trauc\u0113jumi var izrais\u012bt t\u0101dus trauc\u0113jumus k\u0101 Parkinsona slim\u012bba, kad dopam\u012bna tr\u016bkums izraisa motoriskus trauc\u0113jumus, piem\u0113ram, tr\u012bci, st\u012bvumu un bradikin\u0113ziju.<\/p>\n<h4>Atalgojums un motiv\u0101cija:<\/h4>\n<p>Dopam\u012bnam ir galven\u0101 noz\u012bme smadze\u0146u atalgojuma sist\u0113m\u0101. Aktiviz\u0113jot dopam\u012bna receptorus, tas izraisa baudas saj\u016btu un pastiprina uzved\u012bbu, kas rada atalgojumu. \u0160is meh\u0101nisms ir b\u016btisks motiv\u0101cijai, uz m\u0113r\u0137i v\u0113rstai uzved\u012bbai un t\u0101du darb\u012bbu pastiprin\u0101\u0161anai k\u0101 \u0113\u0161ana, socializ\u0113\u0161an\u0101s vai iesaist\u012b\u0161an\u0101s atalgojumu neso\u0161\u0101s pieredz\u0113s.<\/p>\n<h4>Kognit\u012bv\u0101s funkcijas un uzman\u012bba:<\/h4>\n<p>Dopam\u012bnam ir b\u016btiska noz\u012bme kognit\u012bvo funkciju, piem\u0113ram, uzman\u012bbas, atmi\u0146as un izpildfunkciju, nodro\u0161in\u0101\u0161an\u0101. T\u0101 neregul\u0113\u0161ana ir saist\u012bta ar t\u0101d\u0101m slim\u012bb\u0101m k\u0101 uzman\u012bbas defic\u012bta un hiperaktivit\u0101tes sindroms (ADHD), \u0161izofr\u0113nija un citiem kognit\u012bviem trauc\u0113jumiem.<\/p>\n<h4>Garast\u0101vok\u013ca regul\u0113\u0161ana:<\/h4>\n<p>Dopam\u012bns ir iesaist\u012bts garast\u0101vok\u013ca regul\u0113\u0161an\u0101, un zema dopam\u012bner\u0123isk\u0101 aktivit\u0101te ir saist\u012bta ar depresijas, anhedonijas (prieka tr\u016bkuma) un zemas motiv\u0101cijas simptomiem. Turpret\u012b paaugstin\u0101ta dopam\u012bner\u0123isk\u0101 aktivit\u0101te var uzlabot garast\u0101vokli un pa\u0161saj\u016btu. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165017398000198?casa_token=_WgXUbc67x0AAAAA:gcNArdjm0jqg1-6jul6CJuxKSIHLyEOaAOcEoeOqXy9OgLKmV-UqsQ8ntwPvVH4SXJroJ7BM-7I\" target=\"_blank\" rel=\"noopener\"><sup>(25)<\/sup><\/a><\/p>\n<h3>\u0100r\u0113jie faktori, kas stimul\u0113 dopam\u012bna receptorus<\/h3>\n<p>\u0100r\u0113jie faktori, tostarp narkotikas, vielas un vides stimuli, var b\u016btiski ietekm\u0113t dopam\u012bna receptoru aktivit\u0101ti. \u0160\u012bs \u0101r\u0113j\u0101s ietekmes bie\u017ei vien izraisa dopam\u012bna izdal\u012b\u0161anos vai pastiprina t\u0101 darb\u012bbu, k\u0101 rezult\u0101t\u0101 dopam\u012bner\u0123isk\u0101 reakcija ir sp\u0113c\u012bg\u0101ka:<\/p>\n<h4>Atp\u016btas narkotikas:<\/h4>\n<p>T\u0101das vielas k\u0101 koka\u012bns un metamfetam\u012bns palielina dopam\u012bna l\u012bmeni, blo\u0137\u0113jot t\u0101 atpaka\u013csaist\u012b\u0161anu vai palielinot t\u0101 izdal\u012b\u0161anos no presinaptiskiem neironiem. Koka\u012bns inhib\u0113 dopam\u012bna transportierus, nov\u0113r\u0161ot dopam\u012bna reabsorbciju neironos, savuk\u0101rt metamfetam\u012bns stimul\u0113 dopam\u012bna izdal\u012b\u0161anos. \u0160\u012bs narkotikas izraisa intens\u012bvu eiforiju un pastiprin\u0101tu atalgojuma signaliz\u0113\u0161anu, bet var izrais\u012bt ar\u012b atkar\u012bbu un ilgtermi\u0146a neiro\u0137\u012bmisko nel\u012bdzsvarot\u012bbu.<\/p>\n<h4>Nikot\u012bns:<\/h4>\n<p>Nikot\u012bns stimul\u0113 dopam\u012bna izdal\u012b\u0161anos caur nikot\u012bna acetilhol\u012bna receptoriem smadzen\u0113s. Kad nikot\u012bns saist\u0101s ar \u0161iem receptoriem, tas netie\u0161i palielina dopam\u012bna aktivit\u0101ti, veicinot tabakas lieto\u0161anas pat\u012bkam\u0101s un atkar\u012bbu izraiso\u0161\u0101s \u012bpa\u0161\u012bbas.<\/p>\n<h4>Kofe\u012bns:<\/h4>\n<p>Kofe\u012bns darbojas galvenok\u0101rt blo\u0137\u0113jot adenoz\u012bna receptorus, kas savuk\u0101rt palielina dopam\u012bna izdal\u012b\u0161anos. Tas palielina modr\u012bbu, uzlabo garast\u0101vokli un \u012bslaic\u012bgi palielina ener\u0123iju un motiv\u0101ciju.<\/p>\n<h4>Alkohols:<\/h4>\n<p>Alkohola lieto\u0161ana ietekm\u0113 ar\u012b dopam\u012bna l\u012bmeni. Tas var palielin\u0101t dopam\u012bna izdal\u012b\u0161anos, jo \u012bpa\u0161i apvidos, kas saist\u012bti ar atl\u012bdz\u012bbas apstr\u0101di, piem\u0113ram, aklaj\u0101 kodol\u0101. \u0160\u012b palielin\u0101\u0161an\u0101s veicina pat\u012bkamas saj\u016btas, kas saist\u012btas ar alkohola lieto\u0161anu, un pastiprina alkohola lieto\u0161anu, kas var izrais\u012bt atkar\u012bbu. <a href=\"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/jcph.1918\" target=\"_blank\" rel=\"noopener\"><sup>(26)<\/sup><\/a><\/p>\n<h3>Iek\u0161\u0113jie faktori, kas stimul\u0113 dopam\u012bna receptorus<\/h3>\n<p>Papildus \u0101r\u0113jiem stimuliem dopam\u012bner\u0123isko sist\u0113mu regul\u0113 ar\u012b organisma iek\u0161\u0113jie procesi. Iek\u0161\u0113jie faktori, piem\u0113ram, motiv\u0101cija, stress un hormon\u0101l\u0101s sv\u0101rst\u012bbas, var ietekm\u0113t dopam\u012bna receptoru aktivit\u0101ti:<\/p>\n<h4>Stresa reakcija:<\/h4>\n<p>Ak\u016bts stress var izrais\u012bt dopam\u012bna izdal\u012b\u0161anos, kas ir da\u013ca no organisma reakcijas \"c\u012b\u0146a vai b\u0113g\u0161ana\". Lai gan dopam\u012bna izdal\u012b\u0161an\u0101s stresa laik\u0101 \u012bstermi\u0146\u0101 var palielin\u0101t modr\u012bbu un koncentr\u0113\u0161an\u0101s sp\u0113jas, hronisks stress var izjaukt norm\u0101lu dopam\u012bner\u0123isko funkciju, potenci\u0101li veicinot garast\u0101vok\u013ca trauc\u0113jumus, atkar\u012bbu vai kognit\u012bvos trauc\u0113jumus. <a href=\"\/lv\/Sinclair,%20D.,%20Purves-Tyson,%20T.%20D.,%20Allen,%20K.%20M.,%20&amp;%20Weickert,%20C.%20S.%20(2014).%20Impacts%20of%20stress%20and%20sex%20hormones%20on%20dopamine%20neurotransmission%20in%20the%20adolescent%20brain.%20Psychopharmacology,%20231,%201581-1599.\/\"><sup>(27)<\/sup><\/a><\/p>\n<h4>Hormon\u0101l\u0101 ietekme:<\/h4>\n<p>Hormoni, \u012bpa\u0161i estrog\u0113ns un testosterons, var modul\u0113t dopam\u012bna receptoru aktivit\u0101ti. Piem\u0113ram, augst\u0101ks estrog\u0113na l\u012bmenis ir saist\u012bts ar pastiprin\u0101tu dopam\u012bna izdal\u012b\u0161anos, t\u0101p\u0113c sieviet\u0113m noteikt\u0101s menstru\u0101l\u0101 cikla f\u0101z\u0113s var rasties garast\u0101vok\u013ca sv\u0101rst\u012bbas vai motiv\u0101cijas izmai\u0146as. <a href=\"\/lv\/Sinclair,%20D.,%20Purves-Tyson,%20T.%20D.,%20Allen,%20K.%20M.,%20&amp;%20Weickert,%20C.%20S.%20(2014).%20Impacts%20of%20stress%20and%20sex%20hormones%20on%20dopamine%20neurotransmission%20in%20the%20adolescent%20brain.%20Psychopharmacology,%20231,%201581-1599.\/\"><sup>(27)<\/sup><\/a><\/p>\n<h3>Siner\u0123iska iedarb\u012bba un kombin\u0113ti stimuli<\/h3>\n<p>Da\u017ereiz da\u017e\u0101di \u0101r\u0113jie un iek\u0161\u0113jie faktori mijiedarbojas, radot siner\u0123isku dopam\u012bner\u0123isku reakciju, pastiprinot dopam\u012bna izdal\u012b\u0161an\u0101s ietekmi. Piem\u0113ram, kombin\u0113jot fizisk\u0101s aktivit\u0101tes ar soci\u0101lo mijiedarb\u012bbu, var rasties pastiprin\u0101ta dopam\u012bner\u0123isk\u0101 reakcija, jo abas darb\u012bbas atsevi\u0161\u0137i palielina dopam\u012bna izdal\u012b\u0161anos. \u0160is siner\u0123iskais efekts ir \u012bpa\u0161i labv\u0113l\u012bgs garast\u0101vok\u013ca, motiv\u0101cijas un kognit\u012bvo funkciju uzlabo\u0161anai.<\/p>\n<p>Turkl\u0101t, kombin\u0113jot t\u0101das vielas k\u0101 kofe\u012bns un nikot\u012bns, var palielin\u0101ties modr\u012bba un pastiprin\u0101ties atalgojuma saj\u016bta, jo abas vielas stimul\u0113 dopam\u012bna izdal\u012b\u0161anos, izmantojot da\u017e\u0101dus meh\u0101nismus. Tom\u0113r atk\u0101rtota vai p\u0101rm\u0113r\u012bga \u0161\u0101du vielu lieto\u0161ana var izrais\u012bt atkar\u012bbu vai pieradumu dopam\u012bner\u0123isk\u0101s sist\u0113mas p\u0101rm\u0113r\u012bgas stimul\u0113\u0161anas d\u0113\u013c. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/001429999290616C\" target=\"_blank\" rel=\"noopener\"><sup>(28)<\/sup><\/a><\/p>\n<p>&nbsp;<\/p>\n<h2>Dopam\u012bna atpaka\u013csaistes inhib\u012bcija<\/h2>\n<p>Norm\u0101los apst\u0101k\u013cos dopam\u012bns no presinaptiskiem neironiem izdal\u0101s sinaptisk\u0101 spraug\u0101, kur tas saist\u0101s ar postsinaptisko neironu dopam\u012bna receptoriem, izraisot da\u017e\u0101dus efektus. Kad dopam\u012bns ir pabeidzis savu signaliz\u0101cijas funkciju, tas parasti tiek reabsorb\u0113ts atpaka\u013c presinaptiskaj\u0101 neiron\u0101. Tom\u0113r, ja dopam\u012bna atpaka\u013csaist\u012b\u0161anos kav\u0113 noteiktas vielas vai z\u0101les, dopam\u012bns ilg\u0101k paliek sinaptisk\u0101 spraug\u0101, izraisot ilgsto\u0161u dopam\u012bna receptoru stimul\u0101ciju. \u0160\u012b pastiprin\u0101t\u0101 dopam\u012bner\u0123isk\u0101 signaliz\u0101cija var izrais\u012bt sp\u0113c\u012bg\u0101ku eiforijas saj\u016btu, paaugstin\u0101tu motiv\u0101ciju, uzlabotu koncentr\u0113\u0161an\u0101s sp\u0113ju un citus efektus atkar\u012bb\u0101 no ietekm\u0113t\u0101s smadze\u0146u zonas. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0149763405000837?casa_token=0V8nBjY-5BsAAAAA:xKohNM65h2slKNrcSMVT7__lwfPrZDIOVQOcDRI9XdkuefcQ2dhXgl2lIaBSf2V3HeCgzwR03eQ\" target=\"_blank\" rel=\"noopener\"><sup>(29)<\/sup><\/a><\/p>\n<h3>Dopam\u012bna atpaka\u013csaistes inhib\u012bcijas meh\u0101nisms<\/h3>\n<p>Dopam\u012bna atpaka\u013csaistes inhibitori (DRI) darbojas, blo\u0137\u0113jot dopam\u012bna p\u0101rnes\u0113ju (DAT) - olbaltumvielu, kas atbild par dopam\u012bna transport\u0113\u0161anu atpaka\u013c presinaptisk\u0101 neiron\u0101. Nov\u0113r\u0161ot \u0161o reabsorbciju, dopam\u012bns ilg\u0101k saglab\u0101jas sinaps\u0113, izraisot ilgsto\u0161u dopam\u012bna receptoru aktiviz\u0101ciju . \u0160\u0101da palielin\u0101ta dopam\u012bna pieejam\u012bba pastiprina neiromediatora ietekmi uz garast\u0101vokli, kognit\u012bvaj\u0101m funkcij\u0101m un kust\u012bbu kontroli.<\/p>\n<h3>Vielas, kas kav\u0113 dopam\u012bna atpaka\u013csaist\u012b\u0161anos<\/h3>\n<p>Vair\u0101kas vielas, gan \u0101rstnieciskas, gan izklaides vielas, darbojas k\u0101 dopam\u012bna atpaka\u013csaistes inhibitori, da\u017e\u0101dos veidos ietekm\u0113jot dopam\u012bner\u0123isko sist\u0113mu:<\/p>\n<h4><strong>Koka\u012bns<\/strong>:<\/h4>\n<p>Koka\u012bns ir viens no paz\u012bstam\u0101kajiem dopam\u012bna atpaka\u013csaistes inhibitoriem, kas blo\u0137\u0113 DAT, izraisot iev\u0113rojamu dopam\u012bna l\u012bme\u0146a paaugstin\u0101\u0161anos sinaptisk\u0101 spraug\u0101. Tas izraisa sp\u0113c\u012bgu eiforijas saj\u016btu, liel\u0101ku ener\u0123iju un paaugstin\u0101tu modr\u012bbu. Tom\u0113r hroniska koka\u012bna lieto\u0161ana var izrais\u012bt atkar\u012bbu un ilgsto\u0161us dopam\u012bna signaliz\u0101cijas trauc\u0113jumus.<\/p>\n<h4>Amfetam\u012bni:<\/h4>\n<p>Ar\u012b t\u0101das narkotikas k\u0101 metamfetam\u012bns un ekstaz\u012b kav\u0113 dopam\u012bna atpaka\u013csaist\u012b\u0161anos, bet var ar\u012b palielin\u0101t dopam\u012bna izdal\u012b\u0161anos no presinaptiskiem neironiem. \u0160\u012b dubult\u0101 iedarb\u012bba izraisa iev\u0113rojam\u0101ku dopam\u012bna l\u012bme\u0146a paaugstin\u0101\u0161anos, veicinot \u0161o vielu stimul\u0113jo\u0161o iedarb\u012bbu un atkar\u012bbu izraiso\u0161o potenci\u0101lu.<\/p>\n<h4>Da\u017ei antidepresanti:<\/h4>\n<p>Da\u017eus selekt\u012bvos seroton\u012bna-norepinefr\u012bna-dopam\u012bna atpaka\u013csaistes inhibitorus (SSNDRI), piem\u0113ram, bupropionu, lieto depresijas un ADHD \u0101rst\u0113\u0161anai. \u0160\u012bs z\u0101les inhib\u0113 dopam\u012bna (un da\u017ek\u0101rt ar\u012b seroton\u012bna un noradrenal\u012bna) atpaka\u013csaist\u012b\u0161anu, palielinot dopam\u012bna pieejam\u012bbu un uzlabojot garast\u0101vokli, koncentr\u0113\u0161anos un motiv\u0101ciju.<\/p>\n<h4>Metilfenid\u0101ts:<\/h4>\n<p>Metilfenid\u0101ts (Rital\u012bns), ko parasti lieto ADHD \u0101rst\u0113\u0161anai, kav\u0113 dopam\u012bna atpaka\u013csaist\u012b\u0161anos, t\u0101d\u0113j\u0101di palielinot dopam\u012bner\u0123isko aktivit\u0101ti smadze\u0146u zon\u0101s, kas saist\u012btas ar koncentr\u0113\u0161an\u0101s, uzman\u012bbas un uzved\u012bbas kontroli. <a href=\"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/article-abstract\/2608759\" target=\"_blank\" rel=\"noopener\"><sup>(30)<\/sup><\/a><\/p>\n<h3>Dopam\u012bna atpaka\u013csaistes inhib\u012bcijas ietekme<\/h3>\n<p>Dopam\u012bna atpaka\u013csaistes inhib\u0113\u0161ana var b\u016btiski ietekm\u0113t smadzenes un uzved\u012bbu:<\/p>\n<h4>Paaugstin\u0101ta jut\u012bba pret atl\u012bdz\u012bbu:<\/h4>\n<p>T\u0101 k\u0101 dopam\u012bnam ir galven\u0101 noz\u012bme smadze\u0146u atalgojuma sist\u0113m\u0101, t\u0101 atpaka\u013csaistes kav\u0113\u0161ana izraisa liel\u0101ku baudas un atalgojuma saj\u016btu. T\u0101p\u0113c t\u0101das narkotikas k\u0101 koka\u012bns un amfetam\u012bns ir saist\u012btas ar sp\u0113c\u012bgu eiforiju un t\u0101m ir liels \u013caunpr\u0101t\u012bgas izmanto\u0161anas potenci\u0101ls.<\/p>\n<h4>Paaugstin\u0101ta koncentr\u0113\u0161an\u0101s un modr\u012bba:<\/h4>\n<p>Palielinot dopam\u012bna pieejam\u012bbu smadze\u0146u zon\u0101s, kas saist\u012btas ar uzman\u012bbu un izpildfunkcij\u0101m, atpaka\u013csaistes inhibitori var uzlabot koncentr\u0113\u0161an\u0101s sp\u0113jas un modr\u012bbu, kas ir lietder\u012bgi t\u0101du slim\u012bbu \u0101rst\u0113\u0161an\u0101 k\u0101 ADHD.<\/p>\n<h4>garast\u0101vok\u013ca uzlabo\u0161ana:<\/h4>\n<p>Pastiprinot dopam\u012bner\u0123isko aktivit\u0101ti, dopam\u012bna atpaka\u013csaistes inhibitori var uzlabot garast\u0101vokli un mazin\u0101t depresijas simptomus. Tas ir pamats da\u017eu \u0161o inhibitoru k\u0101 antidepresantu lieto\u0161anai. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0149763405000837?casa_token=0V8nBjY-5BsAAAAA:xKohNM65h2slKNrcSMVT7__lwfPrZDIOVQOcDRI9XdkuefcQ2dhXgl2lIaBSf2V3HeCgzwR03eQ\" target=\"_blank\" rel=\"noopener\"><sup>(29)<\/sup><\/a><\/p>\n<h2>Papildin\u0101jumi dopam\u012bna l\u012bme\u0146a paaugstin\u0101\u0161anai<\/h2>\n<p>Ir zin\u0101ms, ka vair\u0101ki uztura bag\u0101tin\u0101t\u0101ji veicina dopam\u012bna receptoru veido\u0161anos, izdal\u012b\u0161anos vai aktivit\u0101ti smadzen\u0113s. \u0160ie uztura bag\u0101tin\u0101t\u0101ji var uzlabot garast\u0101vokli, motiv\u0101ciju, kognit\u012bv\u0101s funkcijas un visp\u0101r\u0113jo labsaj\u016btu, jo \u012bpa\u0161i cilv\u0113kiem ar zemu dopam\u012bner\u0123isko aktivit\u0101ti, piem\u0113ram, cilv\u0113kiem ar depresiju vai uzman\u012bbas trauc\u0113jumiem.<\/p>\n<h4>L-tiroz\u012bns:<\/h4>\n<p>L-tiroz\u012bns ir aminosk\u0101be, kas ir dopam\u012bna prekursors. Tas tiek p\u0101rv\u0113rsts par L-DOPA, kas p\u0113c tam tiek sintez\u0113ts dopam\u012bn\u0101. L-tiroz\u012bna piedevas var pal\u012bdz\u0113t palielin\u0101t dopam\u012bna l\u012bmeni, \u012bpa\u0161i stresa, noguruma vai gar\u012bg\u0101s spriedzes periodos, jo t\u0101s palielina dopam\u012bna sint\u0113zi. <a href=\"https:\/\/neurolaunch.com\/dopamine-brain-food-natural-stacks\/\" target=\"_blank\" rel=\"noopener\"><sup>(31)<\/sup><\/a><\/p>\n<h4>Rhodiola Rosea:<\/h4>\n<p>Rodiola ir adaptog\u0113ns, kas var pal\u012bdz\u0113t mazin\u0101t stresu un nogurumu. T\u0101 var palielin\u0101t dopam\u012bna receptoru jut\u012bbu un palielin\u0101t dopam\u012bna ra\u017eo\u0161anu, t\u0101d\u0113j\u0101di uzlabojot garast\u0101vokli un gar\u012bgo veiktsp\u0113ju stresa apst\u0101k\u013cos. <a href=\"https:\/\/www.mdpi.com\/2076-3921\/12\/8\/1603\" target=\"_blank\" rel=\"noopener\"><sup>(32)<\/sup><\/a><\/p>\n<h4><strong>Omega-3 tauksk\u0101bes<\/strong>:<\/h4>\n<p>Pier\u0101d\u012bts, ka omega 3 tauksk\u0101bes, kas atrodamas zivju e\u013c\u013c\u0101 un da\u017e\u0101s augu e\u013c\u013c\u0101s, palielina dopam\u012bna receptoru bl\u012bvumu un pastiprina dopam\u012bner\u0123isko signaliz\u0101ciju. \u0160ie vesel\u012bgie tauki veicina visp\u0101r\u0113jo smadze\u0146u vesel\u012bbu un dopam\u012bna funkciju. <a href=\"https:\/\/neurolaunch.com\/dopamine-brain-food-natural-stacks\/\" target=\"_blank\" rel=\"noopener\"><sup>(31)<\/sup><\/a><\/p>\n<h4><strong>Kurkum\u012bns<\/strong>:<\/h4>\n<p>Kurkuma akt\u012bv\u0101 viela kurkum\u012bns var pal\u012bdz\u0113t palielin\u0101t dopam\u012bna l\u012bmeni, samazinot iekaisumu un veicinot smadze\u0146u neirotrofisk\u0101 faktora (BDNF) veido\u0161anos, kas veicina dopam\u012bnu ra\u017eojo\u0161o neironu aug\u0161anu. <a href=\"https:\/\/www.mdpi.com\/2076-3921\/12\/8\/1603\" target=\"_blank\" rel=\"noopener\"><sup>(32)<\/sup><\/a><\/p>\n<h4><strong>B6 vitam\u012bns<\/strong>:<\/h4>\n<p>Ir pier\u0101d\u012bts, ka B6 vitam\u012bnam ir noz\u012bme dopam\u012bna receptoru regul\u0113\u0161an\u0101. B6 vitam\u012bna tr\u016bkums var pasliktin\u0101t dopam\u012bna receptoru darb\u012bbu, izraisot garast\u0101vok\u013ca un kognit\u012bvos trauc\u0113jumus. Multivitam\u012bnu papildin\u0101\u0161ana var pal\u012bdz\u0113t uztur\u0113t vesel\u012bgu dopam\u012bna l\u012bmeni. <a href=\"https:\/\/neurolaunch.com\/dopamine-brain-food-natural-stacks\/\" target=\"_blank\" rel=\"noopener\"><sup>(31)<\/sup><\/a><\/p>\n<p>&nbsp;<\/p>\n<h2>Bromant\u0101na ietekme uz dopam\u012bna l\u012bmeni<\/h2>\n<p>Bromant\u0101ns ir nootrops un adaptog\u0113ns ar stimul\u0113jo\u0161\u0101m \u012bpa\u0161\u012bb\u0101m, ko bie\u017ei lieto, lai palielin\u0101tu gar\u012bgo veiktsp\u0113ju, mazin\u0101tu nogurumu un uzlabotu kognit\u012bv\u0101s funkcijas. S\u0101kotn\u0113ji Krievij\u0101 izstr\u0101d\u0101ts ast\u0113nijas (fiziska un gar\u012bga noguruma st\u0101vok\u013ca) \u0101rst\u0113\u0161anai, bromant\u0101ns ir k\u013cuvis popul\u0101rs k\u0101 kognit\u012bvo sp\u0113ju uzlabojo\u0161s l\u012bdzeklis, pateicoties t\u0101 sp\u0113jai ietekm\u0113t da\u017e\u0101das neiromediatoru sist\u0113mas, tostarp dopam\u012bnu. <a href=\"https:\/\/www.ijest.org\/nootropics\/bromantane\/\" target=\"_blank\" rel=\"noopener\"><sup>(33)<\/sup><\/a><\/p>\n<p>Bromant\u0101nam ir unik\u0101ls darb\u012bbas meh\u0101nisms. Tas ir klasific\u0113ts k\u0101 viela bez atkar\u012bbu izraiso\u0161a potenci\u0101la vai izteiktas stimul\u0113jo\u0161as iedarb\u012bbas, kas nov\u0113rojama citiem amfetam\u012bniem. Galven\u0101 bromant\u0101na iedarb\u012bba uz dopam\u012bna l\u012bmeni ir dopam\u012bna sint\u0113zes palielin\u0101\u0161ana, palielinot tiroz\u012bna hidroksil\u0101zes, enz\u012bma, kas atbild\u012bgs par tiroz\u012bna p\u0101rv\u0113r\u0161anu par L-DOPA (dopam\u012bna prekursoru), aktivit\u0101ti. Tas veicina dopam\u012bna l\u012bme\u0146a paaugstin\u0101\u0161anos smadzen\u0113s. \u0160\u0137iet, ka bromantanam piem\u012bt ar\u012b modul\u0113jo\u0161a iedarb\u012bba uz dopam\u012bna receptoriem, uzlabojot receptoru jut\u012bbu, neradot p\u0101rm\u0113r\u012bgu stimul\u0101ciju. Bromant\u0101na dopam\u012bner\u0123isk\u0101 iedarb\u012bba var pal\u012bdz\u0113t uzlabot kognit\u012bv\u0101s funkcijas, piem\u0113ram, uzman\u012bbu, m\u0101c\u012b\u0161anos un atmi\u0146u. Tas ir \u012bpa\u0161i noder\u012bgi tiem, kuri izj\u016bt kognit\u012bvo nogurumu, vai tiem, kuriem nepiecie\u0161ama pr\u0101ta skaidr\u012bba, veicot saspringtus uzdevumus. Tom\u0113r at\u0161\u0137ir\u012bb\u0101 no tradicion\u0101lajiem stimulantiem, piem\u0113ram, amfetam\u012bna vai metilfenid\u0101ta, bromant\u0101ns neizraisa t\u0101du pa\u0161u nervozit\u0101ti vai p\u0101rm\u0113r\u012bgu stimul\u0101ciju, padarot to par smalk\u0101ku kognit\u012bvo funkciju uzlabot\u0101ju. <a href=\"https:\/\/www.ijest.org\/nootropics\/bromantane\/\" target=\"_blank\" rel=\"noopener\"><sup>(33)<\/sup><\/a><\/p>\n<p>Viena no galvenaj\u0101m bromant\u0101na priek\u0161roc\u012bb\u0101m ir t\u0101 adaptog\u0113n\u0101s \u012bpa\u0161\u012bbas. Tas ne tikai paaugstina dopam\u012bna l\u012bmeni, bet ar\u012b veicina nervu sist\u0113mas l\u012bdzsvaru. \u0160\u012b dubult\u0101 iedarb\u012bba pal\u012bdz mazin\u0101t stresu un trauksmi, vienlaikus uzlabojot gar\u012bgo un fizisko veiktsp\u0113ju. Neraugoties uz bromant\u0101na sp\u0113ju palielin\u0101t dopam\u012bner\u0123isko aktivit\u0101ti, tas netiek uzskat\u012bts par atkar\u012bbu izraiso\u0161u l\u012bdzekli, un t\u0101 lieto\u0161ana neizraisa t\u0101du pa\u0161u \"sabrukumu\" vai atkar\u012bbu, kas rakstur\u012bga citiem stimulantiem. \u012as\u0101k sakot, bromant\u0101ns paaugstina dopam\u012bna l\u012bmeni, inhib\u0113jot dopam\u012bna atpaka\u013csaist\u012b\u0161anos un palielinot sint\u0113zi, k\u0101 rezult\u0101t\u0101 uzlabojas kognit\u012bv\u0101s funkcijas, gar\u012bg\u0101 skaidr\u012bba un samazin\u0101s nogurums. T\u0101 ietekme uz dopam\u012bnu ir smalk\u0101ka nek\u0101 tradicion\u0101lajiem stimulantiem, un tam piem\u012bt adaptog\u0113nas \u012bpa\u0161\u012bbas, kas pal\u012bdz uztur\u0113t l\u012bdzsvarotu dopam\u012bner\u0123isko sist\u0113mu. <a href=\"https:\/\/www.ijest.org\/nootropics\/bromantane\/\" target=\"_blank\" rel=\"noopener\"><sup>(33)<\/sup><\/a><\/p>\n<h2>Aniracet\u0101ma ietekme uz dopam\u012bna l\u012bmeni<\/h2>\n<p>Aniracet\u0101ms ir nootrops no racetam dzimtas, ko parasti lieto kognit\u012bvo funkciju uzlabo\u0161anai, atmi\u0146as uzlabo\u0161anai un koncentr\u0113\u0161an\u0101s palielin\u0101\u0161anai. Lai gan tiek uzskat\u012bts, ka t\u0101 galven\u0101 iedarb\u012bba ir uz AMPA receptoriem (kas ir saist\u012bti ar sinaptisko plastiskumu un m\u0101c\u012b\u0161anos), aniracet\u0101ms ietekm\u0113 ar\u012b dopam\u012bna l\u012bmeni un dopam\u012bner\u0123isko aktivit\u0101ti smadzen\u0113s. Tiek uzskat\u012bts, ka aniracet\u0101ms netie\u0161i ietekm\u0113 dopam\u012bna l\u012bmeni, palielinot kop\u0113jo glutamater\u0123isk\u0101s sist\u0113mas aktivit\u0101ti, kas savuk\u0101rt var ietekm\u0113t dopam\u012bna signaliz\u0101ciju. Konkr\u0113ti, tiek uzskat\u012bts, ka aniracet\u0101ms modul\u0113 dopam\u012bner\u0123isko neirotransmisiju, ietekm\u0113jot cAMP (ciklisk\u0101 adenoz\u012bna monofosf\u0101ta) l\u012bmeni. cAMP ir sekund\u0101rais zi\u0146nesis, kam ir b\u016btiska loma dopam\u012bna receptoru regul\u0113\u0161an\u0101 un dopam\u012bna izdal\u012b\u0161an\u0101s proces\u0101. Palielinot cAMP veido\u0161anos, aniracet\u0101ms var palielin\u0101t dopam\u012bna receptoru jut\u012bbu, padarot smadzenes jut\u012bg\u0101kas pret dopam\u012bnu. Turkl\u0101t ir pier\u0101d\u012bts, ka aniracet\u0101ms palielina dopam\u012bna izdal\u012b\u0161anos noteiktos smadze\u0146u re\u0123ionos, tostarp striatum\u0101, kas ir iesaist\u012bts atl\u012bdz\u012bbas apstr\u0101d\u0113 un kust\u012bbu kontrol\u0113. Tas var veicin\u0101t motiv\u0101cijas, garast\u0101vok\u013ca un visp\u0101r\u0113j\u0101s kognit\u012bv\u0101s veiktsp\u0113jas uzlabo\u0161anos, \u012bpa\u0161i uzdevumos, kas prasa koncentr\u0113\u0161anos vai gar\u012bgo piep\u016bli. \u0160is efekts var ar\u012b izskaidrot, k\u0101p\u0113c da\u017ei lietot\u0101ji, lietojot aniracet\u0101mu, zi\u0146o par garast\u0101vok\u013ca uzlabo\u0161anos un pr\u0101ta skaidr\u012bbu, jo dopam\u012bns ir galvenais garast\u0101vok\u013ca regul\u0113\u0161anas dal\u012bbnieks. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006899301029390?casa_token=L4sginq_LmgAAAAA:1Ov9i895A6KNRPNajs5G7t9B2VNCtGoAk9Q3nxRJ1zSggnamw2EArQG0uKPf4ONsg0epNJPjQpg\" target=\"_blank\" rel=\"noopener\"><sup>(34)<\/sup><\/a><\/p>\n<p>Aniracetamamam piem\u012bt ar\u012b neiroprotekt\u012bva iedarb\u012bba, un tas var pal\u012bdz\u0113t saglab\u0101t dopam\u012bner\u0123isko funkciju laika gait\u0101. Da\u017ei p\u0113t\u012bjumi liecina, ka tas var aizsarg\u0101t dopam\u012bna receptorus no oksidat\u012bviem boj\u0101jumiem, kas ir \u012bpa\u0161i svar\u012bgi vesel\u012bgas dopam\u012bna signaliz\u0101cijas uztur\u0113\u0161anai vecum\u0101. \u0160\u012b neiroprotekt\u012bv\u0101 \u012bpa\u0161\u012bba var pal\u012bdz\u0113t nov\u0113rst ar vecumu saist\u012btu kognit\u012bvo funkciju pasliktin\u0101\u0161anos un uztur\u0113t ilgsto\u0161u dopam\u012bner\u0123isko funkciju. Attiec\u012bb\u0101 uz garast\u0101vokli - dopam\u012bna aktivit\u0101tes palielin\u0101\u0161an\u0101s, ko izraisa aniracet\u0101ms, var pal\u012bdz\u0113t mazin\u0101t depresijas, trauksmes vai zemas motiv\u0101cijas simptomus. Pastiprinot dopam\u012bna signaliz\u0101ciju, tas var veicin\u0101t labsaj\u016btu un motiv\u0101ciju, kas bie\u017ei vien ir pasliktin\u0101jusies ar dopam\u012bner\u0123isko disfunkciju saist\u012btos st\u0101vok\u013cos. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006899301029390?casa_token=L4sginq_LmgAAAAA:1Ov9i895A6KNRPNajs5G7t9B2VNCtGoAk9Q3nxRJ1zSggnamw2EArQG0uKPf4ONsg0epNJPjQpg\" target=\"_blank\" rel=\"noopener\"><sup>(34)<\/sup><\/a><\/p>\n<p>Tom\u0113r \u0161\u0137iet, ka aniralet\u0101ms p\u0101rm\u0113r\u012bgi nestimul\u0113 dopam\u012bner\u0123isko sist\u0113mu t\u0101, k\u0101 to dara tie\u0161ie dopam\u012bna atpaka\u013csaistes inhibitori vai stimulanti, piem\u0113ram, amfetam\u012bns. Ietekme uz dopam\u012bnu parasti ir smalka un vair\u0101k v\u0113rsta uz dopam\u012bna receptoru jut\u012bbas modul\u0101ciju, nevis uz lielu dopam\u012bna izdal\u012b\u0161an\u0101s palielin\u0101\u0161anos. T\u0101p\u0113c aniracetamam ir m\u0113rena, bet labv\u0113l\u012bga ietekme uz dopam\u012bna l\u012bmeni, palielinot dopam\u012bna izdal\u012b\u0161anos un paaugstinot receptoru jut\u012bbu. Tas pal\u012bdz kognit\u012bvaj\u0101m funkcij\u0101m un garast\u0101voklim, uzlabojot dopam\u012bner\u0123isko signaliz\u0101ciju smadzen\u0113s, lai gan t\u0101 galven\u0101 ietekme ir uz glutamater\u0123isko sist\u0113mu. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006899301029390?casa_token=L4sginq_LmgAAAAA:1Ov9i895A6KNRPNajs5G7t9B2VNCtGoAk9Q3nxRJ1zSggnamw2EArQG0uKPf4ONsg0epNJPjQpg\" target=\"_blank\" rel=\"noopener\"><sup>(34)<\/sup><\/a><\/p>\n<h2>Teakr\u012bna ietekme uz dopam\u012bna l\u012bmeni<\/h2>\n<p>Teakr\u012bns (paz\u012bstams ar\u012b k\u0101 teakr\u012bns) ir dab\u0101 sastopams alkalo\u012bds, kas atrodams Kucha t\u0113j\u0101 un kafij\u0101 un bie\u017ei tiek izmantots stimul\u0113jo\u0161as un nootropas iedarb\u012bbas d\u0113\u013c. Lai gan struktur\u0101li teakr\u012bns ir l\u012bdz\u012bgs kofe\u012bnam, tam ir at\u0161\u0137ir\u012bgs farmakolo\u0123iskais profils, \u012bpa\u0161i attiec\u012bb\u0101 uz ietekmi uz dopam\u012bnu un citiem neiromediatoriem. Teakr\u012bns galvenok\u0101rt ietekm\u0113 dopam\u012bnu, pateicoties t\u0101 sp\u0113jai palielin\u0101t dopam\u012bna izdal\u012b\u0161anos noteiktos smadze\u0146u re\u0123ionos. T\u0101pat k\u0101 kofe\u012bns, teakr\u012bns darbojas, blo\u0137\u0113jot adenoz\u012bna receptorus, kas ir saist\u012bti ar relaks\u0101cijas un miega veicin\u0101\u0161anu. Antagoniz\u0113jot \u0161os receptorus, teakr\u012bns veicina modr\u012bbu un modr\u012bbu. Tom\u0113r teakr\u012bns neizraisa t\u0101du nervozit\u0101ti vai ener\u0123ijas kritumu, k\u0101du var izrais\u012bt kofe\u012bns. <a href=\"https:\/\/magistralbr.caldic.com\/storage\/product-files\/624080992.pdf\" target=\"_blank\" rel=\"noopener\"><sup>(35)<\/sup><\/a><\/p>\n<p>Viens no galvenajiem veidiem, k\u0101 teakr\u012bns iedarbojas uz dopam\u012bnu, ir caur dopam\u012bna D2 receptoriem. P\u0113t\u012bjumi liecina, ka teakr\u012bns var palielin\u0101t dopam\u012bna izdal\u012b\u0161anos ar motiv\u0101ciju un atl\u012bdz\u012bbu saist\u012btaj\u0101s smadze\u0146u zon\u0101s, piem\u0113ram, prefront\u0101laj\u0101 garoz\u0101 un striatum\u0101. Tas uzlabo garast\u0101vokli, koncentr\u0113\u0161an\u0101s sp\u0113jas un kognit\u012bvo veiktsp\u0113ju, l\u012bdz\u012bgi k\u0101 tradicion\u0101lie stimulanti, bet bez p\u0101rm\u0113r\u012bgas stimul\u0101cijas un atkar\u012bbas riska, kas saist\u012bts ar t\u0101d\u0101m viel\u0101m k\u0101 kofe\u012bns vai amfetam\u012bni. Teakr\u012bnam ir ar\u012b ilgsto\u0161\u0101ka iedarb\u012bba sal\u012bdzin\u0101jum\u0101 ar kofe\u012bnu. Kam\u0113r kofe\u012bna iedarb\u012bba parasti sasniedz maksimumu un izz\u016bd da\u017eu stundu laik\u0101, Teakr\u012bns nodro\u0161ina ilgsto\u0161u kognit\u012bvo un garast\u0101vokli uzlabojo\u0161u iedarb\u012bbu ilg\u0101k\u0101 laika period\u0101, kas var pal\u012bdz\u0113t uztur\u0113t konsekventu dopam\u012bna signaliz\u0101ciju visas dienas garum\u0101. \u0160\u012b ilgsto\u0161\u0101 iedarb\u012bba da\u013c\u0113ji ir saist\u012bta ar teakr\u012bna ietekmi uz dopam\u012bna receptoru jut\u012bbu un sp\u0113ju laika gait\u0101 pak\u0101peniski palielin\u0101t dopam\u012bna izdal\u012b\u0161anos. <a href=\"https:\/\/magistralbr.caldic.com\/storage\/product-files\/624080992.pdf\" target=\"_blank\" rel=\"noopener\"><sup>(35)<\/sup><\/a><\/p>\n<p>Turkl\u0101t teakr\u012bnam piem\u012bt neiroprotekt\u012bvas \u012bpa\u0161\u012bbas, kas var pal\u012bdz\u0113t aizsarg\u0101t dopam\u012bnu ra\u017eojo\u0161os neironus no boj\u0101jumiem. Tas var b\u016bt noder\u012bgi vesel\u012bgas dopam\u012bner\u0123isk\u0101s funkcijas uztur\u0113\u0161anai, jo \u012bpa\u0161i cilv\u0113kiem, kuri izj\u016bt kognit\u012bvo nogurumu vai stresu. Pastiprin\u0101tas dopam\u012bna atbr\u012bvo\u0161an\u0101s, ilgsto\u0161as iedarb\u012bbas un garast\u0101vokli uzlabojo\u0161u \u012bpa\u0161\u012bbu kombin\u0101cija padara teakr\u012bnu par popul\u0101ru izv\u0113li tiem, kas mekl\u0113 nootropu l\u012bdzekli, kas atbalsta gan kognit\u012bvo veiktsp\u0113ju, gan emocion\u0101lo labsaj\u016btu bez atkar\u012bbas vai tolerances riska, kas saist\u012bts ar citiem stimulantiem. T\u0101p\u0113c Theacrine ne tikai palielina dopam\u012bna izdal\u012b\u0161anos un receptoru aktivit\u0101ti, t\u0101d\u0113j\u0101di uzlabojot garast\u0101vokli, motiv\u0101ciju un kognit\u012bv\u0101s funkcijas, bet ar\u012b nodro\u0161ina pak\u0101penisku un ilgsto\u0161u iedarb\u012bbu, padarot to par maig\u0101ku alternat\u012bvu citiem stimulantiem. <a href=\"https:\/\/magistralbr.caldic.com\/storage\/product-files\/624080992.pdf\" target=\"_blank\" rel=\"noopener\"><sup>(35)<\/sup><\/a><\/p>\n<h2>Mucuna ietekme uz dopam\u012bna l\u012bmeni<\/h2>\n<p>Mucuna pruriens, paz\u012bstama ar\u012b k\u0101 samta pupi\u0146as, ir tropu augs, ko tradicion\u0101laj\u0101 medic\u012bn\u0101 jau sen izmanto terapeitisk\u0101s iedarb\u012bbas d\u0113\u013c, \u012bpa\u0161i Parkinsona slim\u012bbas un seksu\u0101l\u0101s disfunkcijas \u0101rst\u0113\u0161an\u0101. Mucuna pruriens galven\u0101 sast\u0101vda\u013ca, kas ietekm\u0113 dopam\u012bna iedarb\u012bbu, ir L-DOPA, kas ir tie\u0161s dopam\u012bna prekursors. L\u012bdz ar to Mucuna pruriens ir sp\u0113c\u012bgs dab\u012bgs dopam\u012bna prekursors, kas var iev\u0113rojami paaugstin\u0101t dopam\u012bna l\u012bmeni smadzen\u0113s. Mucuna pruriens bie\u017ei lieto k\u0101 uztura bag\u0101tin\u0101t\u0101ju, lai pal\u012bdz\u0113tu paaugstin\u0101t dopam\u012bna l\u012bmeni cilv\u0113kiem ar dopam\u012bna defic\u012btu, piem\u0113ram, Parkinsona slim\u012bbas slimniekiem. L-DOPA no mokunas tiek p\u0101rv\u0113rsts dopam\u012bn\u0101, iedarbojoties enz\u012bma dopam\u012bna dekarboksil\u0101zes darb\u012bbai. Tas pal\u012bdz atjaunot dopam\u012bna darb\u012bbu smadze\u0146u zon\u0101s, kas saist\u012btas ar kust\u012bbu kontroli, atalgojumu un garast\u0101vok\u013ca regul\u0101ciju. Palielinot L-DOPA pieejam\u012bbu, Mucuna pruriens var pal\u012bdz\u0113t palielin\u0101t dopam\u012bna ra\u017eo\u0161anu smadzen\u0113s, t\u0101d\u0113j\u0101di uzlabojot kust\u012bbu kontroli, garast\u0101vokli un motiv\u0101ciju. \u0160is efekts ir \u012bpa\u0161i svar\u012bgs cilv\u0113kiem, kas slimo ar t\u0101d\u0101m slim\u012bb\u0101m k\u0101 Parkinsona slim\u012bba, kuras laik\u0101 smadzen\u0113s de\u0123ener\u0113jas dopam\u012bnu ra\u017eojo\u0161ie neironi, izraisot kust\u012bbu trauc\u0113jumus un garast\u0101vok\u013ca trauc\u0113jumus. <a href=\"https:\/\/www.rjpponline.org\/HTML_Papers\/Research%20Journal%20of%20Pharmacognosy%20and%20Phytochemistry__PID__2024-16-4-15.html\" target=\"_blank\" rel=\"noopener\"><sup>(36)<\/sup><\/a><\/p>\n<p>Papildus Parkinsona slim\u012bbai mucuna dopam\u012bner\u0123isk\u0101 iedarb\u012bba var b\u016bt noder\u012bga ar\u012b cilv\u0113kiem, kuri cie\u0161 no depresijas, stresa vai zemas motiv\u0101cijas, jo dopam\u012bnam ir b\u016btiska noz\u012bme garast\u0101vok\u013ca regul\u0113\u0161an\u0101 un atl\u012bdz\u012bbas apstr\u0101d\u0113. Mucuna var uzlabot garast\u0101vokli un visp\u0101r\u0113jo labsaj\u016btu, papildinot dopam\u012bna l\u012bmeni. Papildus dopam\u012bna ra\u017eo\u0161anas palielin\u0101\u0161anai mukunai piem\u012bt neiroprotekt\u012bva iedarb\u012bba. P\u0113t\u012bjumi liecina, ka t\u0101 var pal\u012bdz\u0113t aizsarg\u0101t dopam\u012bnu ra\u017eojo\u0161os neironus no oksidat\u012bv\u0101 stresa, kas laika gait\u0101 var izrais\u012bt neironu boj\u0101jumus. Tas ir \u012bpa\u0161i labv\u0113l\u012bgi dopam\u012bna funkcijas saglab\u0101\u0161anai smadzen\u0113s, \u012bpa\u0161i noveco\u0161an\u0101s vai neirode\u0123enerat\u012bvu slim\u012bbu gad\u012bjumos. <a href=\"https:\/\/www.rjpponline.org\/HTML_Papers\/Research%20Journal%20of%20Pharmacognosy%20and%20Phytochemistry__PID__2024-16-4-15.html\" target=\"_blank\" rel=\"noopener\"><sup>(36)<\/sup><\/a><\/p>\n<p>Kopum\u0101 Mucuna pruriens palielina dopam\u012bna l\u012bmeni, nodro\u0161inot dabisku L-DOPA avotu, kas smadzen\u0113s tiek p\u0101rv\u0113rsts par dopam\u012bnu. Tas uzlabo garast\u0101vokli, kognit\u012bv\u0101s un motorisk\u0101s funkcijas, un t\u0101 neiroprotekt\u012bv\u0101s \u012bpa\u0161\u012bbas padara to par v\u0113rt\u012bgu uztura bag\u0101tin\u0101t\u0101ju vesel\u012bgas dopam\u012bner\u0123isk\u0101s aktivit\u0101tes uztur\u0113\u0161anai. <a href=\"https:\/\/www.rjpponline.org\/HTML_Papers\/Research%20Journal%20of%20Pharmacognosy%20and%20Phytochemistry__PID__2024-16-4-15.html\" target=\"_blank\" rel=\"noopener\"><sup>(36)<\/sup><\/a><\/p>\n<h2>Dopam\u012bna l\u012bme\u0146a noteik\u0161ana - dopam\u012bner\u0123isk\u0101s iedarb\u012bbas stimul\u0113\u0161ana pa\u0161am!<\/h2>\n<p>Dopam\u012bns ir \u0137\u012bmisk\u0101 viela, kas smadzen\u0113s rada \"labas saj\u016btas\", ir saist\u012bts ar motiv\u0101ciju, atalgojumu un baudu. Dopam\u012bna l\u012bme\u0146a paaugstin\u0101\u0161ana dabisk\u0101 veid\u0101, veicot ikdienas aktivit\u0101tes, var uzlabot garast\u0101vokli, koncentr\u0113\u0161an\u0101s sp\u0113jas un motiv\u0101ciju. L\u016bk, da\u017ei vienk\u0101r\u0161i veidi, k\u0101 stimul\u0113t dopam\u012bna l\u012bmeni sav\u0101 ikdien\u0101. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11223451\/\" target=\"_blank\" rel=\"noopener\"><sup>(37)) <\/sup><\/a><a href=\"https:\/\/philpapers.org\/rec\/MALTBN\" target=\"_blank\" rel=\"noopener\"><sup>((38)<\/sup><\/a>:<\/p>\n<h4>Izvirziet sev nelielus m\u0113r\u0137us:<\/h4>\n<p>Mazu uzdevumu izpilde, piem\u0113ram, vair\u0101ku punktu atz\u012bm\u0113\u0161ana dar\u0101mo darbu sarakst\u0101, izraisa dopam\u012bna izdal\u012b\u0161anos. Katrs neliels sasniegums sniedz gandar\u012bjuma saj\u016btu, kas motiv\u0113 turpin\u0101t darbu.<\/p>\n<h4>Regul\u0101ri vingrojiet:<\/h4>\n<p>Fizisk\u0101s aktivit\u0101tes - pastaigas, joga vai treni\u0146i - palielina dopam\u012bna l\u012bmeni, stimul\u0113jot t\u0101 izdal\u012b\u0161anos. Nodarb\u012bbas ne tikai palielina dopam\u012bna l\u012bmeni, bet ar\u012b atbr\u012bvo citas garast\u0101vokli uzlabojo\u0161as \u0137\u012bmisk\u0101s vielas, piem\u0113ram, seroton\u012bnu un endorf\u012bnus.<\/p>\n<h4>\u0112diet p\u0101rtikas produktus, kas palielina dopam\u012bna l\u012bmeni:<\/h4>\n<p>Tiroz\u012bna bag\u0101ti p\u0101rtikas produkti (piem\u0113ram, liellopu ga\u013ca, olas un pupi\u0146as) ir b\u016btiski dopam\u012bna ra\u017eo\u0161anai. Ar\u012b t\u0101di aug\u013ci k\u0101 ban\u0101ni un bietes un pat tum\u0161\u0101 \u0161okol\u0101de pal\u012bdz paaugstin\u0101t dopam\u012bna l\u012bmeni.<\/p>\n<h4>Labi izgulieties:<\/h4>\n<p>Miega tr\u016bkums var samazin\u0101t dopam\u012bna receptoru jut\u012bbu, t\u0101d\u0113j\u0101di apgr\u016btinot motiv\u0101cijas saj\u016btu. Lai uztur\u0113tu optim\u0101lu dopam\u012bna funkciju, centieties gul\u0113t 7-9 stundas.<\/p>\n<h4>Klausieties m\u016bziku:<\/h4>\n<p>M\u012b\u013c\u0101k\u0101s dziesmas var paaugstin\u0101t dopam\u012bna l\u012bmeni, \u012bpa\u0161i tad, ja t\u0101s uzlabo garast\u0101vokli vai emocion\u0101li iesaista. M\u016bzika aktiviz\u0113 smadze\u0146u atalgojuma sist\u0113mu, sniedzot jums \u0101tru dopam\u012bna devu.<\/p>\n<h4>Soci\u0101l\u0101 mijiedarb\u012bba:<\/h4>\n<p>Pozit\u012bva soci\u0101l\u0101 mijiedarb\u012bba ar \u0123imeni, draugiem vai kol\u0113\u0123iem izraisa dopam\u012bna izdal\u012b\u0161anos. Pat laipni darbi vai atzin\u012bbas sa\u0146em\u0161ana var uzlabot garast\u0101vokli.<\/p>\n<h4>Jaunu lietu apguve:<\/h4>\n<p>Jaunums stimul\u0113 dopam\u012bna l\u012bmeni. Jaunu aktivit\u0101\u0161u izm\u0113\u0123in\u0101\u0161ana, kaut k\u0101 jauna apg\u016b\u0161ana vai rut\u012bnas mai\u0146a var paaugstin\u0101t dopam\u012bna l\u012bmeni, sniedzot gandar\u012bjumu par piedz\u012bvoto. \u0160\u0101du darb\u012bbu iek\u013cau\u0161ana ikdienas rut\u012bn\u0101 var apzin\u0101ti palielin\u0101t dopam\u012bna ra\u017eo\u0161anu, t\u0101d\u0113j\u0101di uzlabojot garast\u0101vokli un motiv\u0101ciju.<\/p>\n<h2>Smadze\u0146u biohacks dopam\u012bna l\u012bme\u0146a paaugstin\u0101\u0161anai - no neirozin\u0101tnieka perspekt\u012bvas<\/h2>\n<p>\u0160eit ir da\u017ei smadze\u0146u \"hacks\", kas var pal\u012bdz\u0113t stimul\u0113t dopam\u012bna ra\u017eo\u0161anu, uzlabojot garast\u0101vokli, koncentr\u0113\u0161an\u0101s sp\u0113jas un motiv\u0101ciju. \u0160\u012bs vienk\u0101r\u0161\u0101s aktivit\u0101tes var viegli iek\u013caut sav\u0101 ikdienas dz\u012bv\u0113:<\/p>\n<h3>iecien\u012btu \u0113dienu (vai saldumu) \u0113\u0161ana.<\/h3>\n<p>\u0112dot kaut ko iecien\u012btu, piem\u0113ram, iecien\u012btu desertu vai uzkodas, var izrais\u012bt dopam\u012bna izdal\u012b\u0161anos. Bauda, ko sag\u0101d\u0101 kaut kas gar\u0161\u012bgs, ir dabisks uzmundrino\u0161s l\u012bdzeklis. Tom\u0113r galvenais ir iev\u0113rot m\u0113ren\u012bbu, jo p\u0101r\u0113\u0161an\u0101s var izrais\u012bt v\u0113l\u0101ku \"sabrukumu\". Bie\u017ei vien \u0161is veids tiek izmantots p\u0101rm\u0113r\u012bgi, ja m\u0113s ner\u016bp\u0113jamies par citiem dopam\u012bna izrais\u012bt\u0101jiem, kas var novest pie aptauko\u0161an\u0101s. <a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2018.00271\/full\" target=\"_blank\" rel=\"noopener\"><sup>(39)<\/sup><\/a><\/p>\n<h3>Dopam\u012bna aizpl\u016b\u0161ana soci\u0101lajos medijos<\/h3>\n<p>Ritinot soci\u0101los medijus, var rasties dopam\u012bna uzpl\u016bdi, ta\u010du bie\u017ei vien tas dr\u012bz\u0101k izraisa \"dopam\u012bna izpl\u016bdi\", nevis re\u0101lu pieaugumu. Past\u0101v\u012bgi pazi\u0146ojumi un \"pat\u012bk\" izraisa nelielu dopam\u012bna atbr\u012bvo\u0161anos, ta\u010du laika gait\u0101 tas var rad\u012bt maz\u0101k noz\u012bm\u012bgu gandar\u012bjumu. Ierobe\u017eojiet soci\u0101lo pla\u0161sazi\u0146as l\u012bdzek\u013cu lieto\u0161anu, lai izvair\u012btos no izs\u012bkuma saj\u016btas un uzlabotu tie\u0161saistes mijiedarb\u012bbas kvalit\u0101ti. <a href=\"https:\/\/www.malone.edu\/files\/resources\/revised-final-thesis-2020.pdf\" target=\"_blank\" rel=\"noopener\"><sup>(40)<\/sup><\/a><\/p>\n<h3>Aukst\u0101 du\u0161a<\/h3>\n<p>Auksta du\u0161a vai auksta \u016bdens vanna ir \u0101trs veids, k\u0101 palielin\u0101t dopam\u012bna l\u012bmeni. Auksts \u016bdens palielina modr\u012bbu, mazina stresu un ir pier\u0101d\u012bts, ka, palielinot dopam\u012bna receptoru bl\u012bvumu, tas uzlabo garast\u0101vokli. Dopam\u012bna balvu var sniegt ar\u012b sasnieguma saj\u016bta p\u0113c aukstas du\u0161as lieto\u0161anas. <a href=\"https:\/\/cyberleninka.ru\/article\/n\/dopamine-friend-or-foe\" target=\"_blank\" rel=\"noopener\"><sup>(41)<\/sup><\/a><\/p>\n<h3>Saules gaismas iedarb\u012bba<\/h3>\n<p>Dabisk\u0101 saules gaisma pal\u012bdz paaugstin\u0101t dopam\u012bna l\u012bmeni. Saules gaisma veicina seroton\u012bna un dopam\u012bna veido\u0161anos, pal\u012bdzot uzlabot garast\u0101vokli un ener\u0123ijas l\u012bmeni. Centieties katru dienu vismaz 15 min\u016btes uztur\u0113ties saules gaism\u0101, \u012bpa\u0161i no r\u012bta, lai dabiski palielin\u0101tu dopam\u012bna l\u012bmeni. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0278584610003659?casa_token=HHGtLe3xkVoAAAAA:aQCGpVInSd0B4jp2R4SdyYD1rQYsAyxrxmXyvCkxjbZJOLhCvh_nbS_MOicrJQqhDHB6ZoNezlw\" target=\"_blank\" rel=\"noopener\"><sup>(42)<\/sup><\/a><\/p>\n<h2>Atruna<\/h2>\n<p>\u0160is raksts ir rakst\u012bts izgl\u012btojo\u0161os nol\u016bkos, un t\u0101 m\u0113r\u0137is ir veicin\u0101t izpratni par apl\u016bkojamo vielu. Ir svar\u012bgi atz\u012bm\u0113t, ka raksts ir par vielu kopum\u0101 - tas nav konkr\u0113ta produkta (\u0137\u012bmisk\u0101 rea\u0123enta) apraksts. M\u0113s neierosin\u0101m lietot \u0137\u012bmiskos rea\u0123entus cilv\u0113kiem - to aizliedz likums, lai produktu var\u0113tu izmantot \u0101rst\u0113\u0161anai, tam j\u0101b\u016bt re\u0123istr\u0113tam k\u0101 medikamentam. Tekst\u0101 ietvert\u0101 inform\u0101cija ir balst\u012bta uz pieejamajiem zin\u0101tniskajiem p\u0113t\u012bjumiem, un t\u0101 nav paredz\u0113ta k\u0101 medic\u012bnisks padoms vai pa\u0161\u0101rst\u0113\u0161an\u0101s veicin\u0101\u0161ana. Las\u012bt\u0101jam par visiem vesel\u012bbas un \u0101rst\u0113\u0161anas l\u0113mumiem j\u0101konsult\u0113jas ar kvalific\u0113tu vesel\u012bbas apr\u016bpes speci\u0101listu.<\/p>\n<p>&nbsp;<\/p>\n<h2>Atsauces:<\/h2>\n<ol>\n<li>Berke, J. D. (2018). Ko noz\u012bm\u0113 dopam\u012bns? <em>Dabas neirozin\u0101tne<\/em>, <em>21<\/em>(6), 787-793.<\/li>\n<li>Misu, Y., &amp; Goshima, Y. (Eds.). (2005). <em>DOPA k\u0101 neirotransmitera neirobiolo\u0123ija<\/em>. CRC Press.<\/li>\n<li>Ben-Jonathan, N. (1985). Dopam\u012bns: prolakt\u012bnu inhib\u0113jo\u0161s hormons. <em>Endokr\u012bn\u0101s sist\u0113mas atsauksmes<\/em>, <em>6<\/em>(4), 564-589.<\/li>\n<li>Dreyer, D. R., Miller, D. J., Freeman, B. D., Paul, D. R., &amp; Bielawski, C. W. (2012). Poli (dopam\u012bna) strukt\u016bras noskaidro\u0161ana. <em>Langmuira<\/em>, <em>28<\/em>(15), 6428-6435.<\/li>\n<li>Krzymowski, T., &amp; Stefa\u0144czyk-Krzymowska, S. (2015). Jauni fakti un koncepcija par dopam\u012bner\u0123isk\u0101s sist\u0113mas funkcijas fiziolo\u0123isko regul\u0101ciju un t\u0101s trauc\u0113jumiem. <em>J Physiol Pharmacol<\/em>, <em>66<\/em>(3), 331-341.<\/li>\n<li>Neumann, J., Hofmann, B., Dhein, S., &amp; Gergs, U. (2023). Sirds dopam\u012bna loma vesel\u012bb\u0101 un slim\u012bb\u0101. <em>International Journal of Molecular Sciences<\/em>, <em>24<\/em>(5), 5042.<\/li>\n<li>Dive, A., Foret, F., Jamart, J., Bulpa, P., &amp; Install\u00e9, E. (2000). Dopam\u012bna ietekme uz ku\u0146\u0123a un zarnu trakta motoriku kritiskas slim\u012bbas laik\u0101. <em>Intens\u012bv\u0101s apr\u016bpes medic\u012bna<\/em>, <em>26<\/em>, 901-907.<\/li>\n<li>Liu, C., &amp; Kaeser, P. S. (2019). Dopam\u012bna izdal\u012b\u0161an\u0101s meh\u0101nismi un regul\u0101cija. <em>Pa\u0161reiz\u0113jais viedoklis neirozin\u0101tn\u0113<\/em>, <em>57<\/em>, 46-53.<\/li>\n<li>Beaulieu, J. M., Espinoza, S., &amp; Gainetdinov, R. R. (2015). Dopam\u012bna receptori-IUPHAR R eview 13. <em>Britu farmakolo\u0123ijas \u017eurn\u0101ls<\/em>, <em>172<\/em>(1), 1-23.<\/li>\n<li>Janhunen, S., &amp; Ahtee, L. (2007). Nigrostriat\u0101l\u0101 un mezolimbisk\u0101 dopam\u012bner\u0123isk\u0101 ce\u013ca diferenci\u0101la nikot\u012bna regul\u0101cija: ietekme uz z\u0101\u013cu izstr\u0101di. <em>Neirozin\u0101tne &amp; Biobehavioral Atsauksmes<\/em>, <em>31<\/em>(3), 287-314.<\/li>\n<li>Yokochi, M. (2007). Mezolimbiskie un mezokortik\u0101lie ce\u013ci Parkinsona slim\u012bbas gad\u012bjum\u0101. <em>Smadzenes un nervi = Shinkei kenkyu no shinpo<\/em>, <em>59<\/em>(9), 943-951.<\/li>\n<li>Amenta, F., Ricci, A., Tayebati, S. K., &amp; Zaccheo, D. (2002). Perif\u0113r\u0101 dopam\u012bner\u0123isk\u0101 sist\u0113ma: morfolo\u0123isk\u0101 anal\u012bze, funkcion\u0101l\u0101 un kl\u012bnisk\u0101 pielieto\u0161ana. <em>It\u0101lijas anatomijas un embriolo\u0123ijas \u017eurn\u0101ls<\/em>, <em>107<\/em>(3), 145-167.<\/li>\n<li>Hashemi, P., Dankoski, E. C., Lama, R., Wood, K. M., Takmakov, P., &amp; Wightman, R. M. (2012). Dopam\u012bns un seroton\u012bns smadzen\u0113s at\u0161\u0137iras p\u0113c to regul\u0101cijas un sek\u0101m. <em>Nacion\u0101l\u0101s zin\u0101t\u0146u akad\u0113mijas kr\u0101jums (Proceedings of the National Academy of Sciences)<\/em>, <em>109<\/em>(29), 11510-11515.<\/li>\n<li>Lambert, G., Johansson, M., \u00c5gren, H., &amp; Friberg, P. (2000). Samazin\u0101ta norepinefr\u012bna un dopam\u012bna izdal\u012b\u0161an\u0101s smadzen\u0113s \u0101rst\u0113\u0161anai rezistentas depres\u012bvas slim\u012bbas gad\u012bjum\u0101: pier\u0101d\u012bjumi, kas apstiprina kateholam\u012bnu hipot\u0113zi par garast\u0101vok\u013ca trauc\u0113jumiem. <em>Archives of general psychiatry<\/em>, <em>57<\/em>(8), 787-793.<\/li>\n<li>Qi, Z., Kikuchi, S., Tretter, F., &amp; Voit, E. O. (2011). Dopam\u012bna un glutam\u0101ta ietekme uz sinaptisko plastiskumu: datormodel\u0113\u0161anas pieeja narkom\u0101nijai k\u0101 komorbidit\u0101tei garast\u0101vok\u013ca trauc\u0113jumu gad\u012bjum\u0101. <em>Farmakopsihiatrija<\/em>, <em>44<\/em>(S 01), S62-S75.<\/li>\n<li>Narvaes, R., &amp; Martins de Almeida, R. M. (2014). Agres\u012bva uzved\u012bba un tr\u012bs neiromediatori: dopam\u012bns, GABA un seroton\u012bns - p\u0113d\u0113jo 10 gadu p\u0101rskats. <em>Psiholo\u0123ija un neirozin\u0101tne<\/em>, <em>7<\/em>(4), 601.<\/li>\n<li>Boesgaard, S., Hagen, C., Andersen, A. N., Fenger, M., &amp; Eldrup, E. (1990). Dopam\u012bna, dopam\u012bna D-1 un D-2 receptoru modul\u0101cijas ietekme uz AKTH un kortizola l\u012bmeni norm\u0101liem v\u012brie\u0161iem un sieviet\u0113m. <em>European Journal of Endocrinology<\/em>, <em>122<\/em>(1), 29-36.<\/li>\n<li>Petersson, M., &amp; Uvn\u00e4s-Moberg, K. (2024). Oksitoc\u012bna un dopam\u012bna mijiedarb\u012bba - ietekme uz uzved\u012bbu vesel\u012bbas un slim\u012bbas gad\u012bjum\u0101. <em>Biomedic\u012bna<\/em>, <em>12<\/em>(11), 2440.<\/li>\n<li>Zheng, R. (2022). Prieks un sasniegumi: Dopam\u012bns un endorf\u012bni. <em>Svar\u012bg\u0101kie notikumi zin\u0101tn\u0113, in\u017eenierzin\u0101tn\u0113s un tehnolo\u0123ij\u0101s<\/em>, <em>6<\/em>, 83-89.<\/li>\n<li>Imperato, A., Puglisi-Allegra, S., Casolini, P., &amp; Angelucci, L. (1991). Smadze\u0146u dopam\u012bna un acetilhol\u012bna izdal\u012b\u0161an\u0101s izmai\u0146as stresa laik\u0101 un p\u0113c stresa ir neatkar\u012bgas no hipof\u012bzes un virsnieru garozas ass. <em>Smadze\u0146u izp\u0113te<\/em>, <em>538<\/em>(1), 111-117.<\/li>\n<li>Bressan, R. A., &amp; Crippa, J. A. (2005). Dopam\u012bna loma atl\u012bdz\u012bbas un baudas uzved\u012bb\u0101 - pirmskl\u012bnisko p\u0113t\u012bjumu datu p\u0101rskats. <em>Acta Psychiatrica Scandinavica<\/em>, <em>111<\/em>, 14-21.<\/li>\n<li>Leyton, M. (2010). V\u0113lmes neirobiolo\u0123ija: Dopam\u012bns un garast\u0101vok\u013ca un motiv\u0101cijas st\u0101vok\u013cu regul\u0101cija cilv\u0113kiem.<\/li>\n<li>Heller, R. (2011). Pat\u0113r\u0113t\u0101ju skrejceli\u0146a pal\u0113nin\u0101\u0161ana. <em>Hum\u0101nists<\/em>, <em>71<\/em>(4), 30.<\/li>\n<li>Oishi, Y., &amp; Lazarus, M. (2017). Miega un nomoda kontrole ar mezolimbisko dopam\u012bna sist\u0113mu pal\u012bdz\u012bbu. <em>Neirozin\u0101tnes p\u0113t\u012bjumi<\/em>, <em>118<\/em>, 66-73.<\/li>\n<li>Berridge, K. C., &amp; Robinson, T. E. (1998). K\u0101da ir dopam\u012bna loma atalgojum\u0101: hedonisks afekts, atalgojuma apguve vai stimulu noz\u012bm\u012bgums? <em>Smadze\u0146u p\u0113tniec\u012bbas p\u0101rskati<\/em>, <em>28<\/em>(3), 309-369.<\/li>\n<li>Docherty, J. R., &amp; Alsufyani, H. A. (2021). Par stimulantiem lietoto z\u0101\u013cu farmakolo\u0123ija. <em>Journal of Clinical Pharmacology<\/em>, <em>61<\/em>, S53-S69.<\/li>\n<li>Sinclair, D., Purves-Tyson, T. D., Allen, K. M., &amp; Weickert, C. S. (2014). Stresa un dzimumhormonu ietekme uz dopam\u012bna neirotransmisiju pusaud\u017eu smadzen\u0113s. <em>Psihofarmakolo\u0123ija<\/em>, <em>231<\/em>, 1581-1599.<\/li>\n<li>Martin-Iverson, M. T., &amp; Yamada, N. (1992). Dopam\u012bna D1 un D2 receptoru agonistu siner\u0123isko iedarb\u012bbu uz uzved\u012bb\u0101 nosaka diennakts ritmi. <em>European journal of pharmacology<\/em>, <em>215<\/em>(1), 119-125.<\/li>\n<li>Young, A. M., Moran, P. M., &amp; Joseph, M. H. (2005). Dopam\u012bna loma kondicion\u0113\u0161an\u0101 un latentaj\u0101 inhib\u012bcij\u0101: kas, kad, kur un k\u0101? <em>Neirozin\u0101tne &amp; Biobehavioral Atsauksmes<\/em>, <em>29<\/em>(6), 963-976.<\/li>\n<li>Ashok, A. H., Mizuno, Y., Volkow, N. D., &amp; Howes, O. D. (2017). Stimulantu lieto\u0161anas saist\u012bba ar dopam\u012bner\u0123iskaj\u0101m izmai\u0146\u0101m koka\u012bna, amfetam\u012bna vai metamfetam\u012bna lietot\u0101jiem: sistem\u0101tisks p\u0101rskats un metaanal\u012bze. <em>JAMA psihiatrija<\/em>, <em>74<\/em>(5), 511-519.<\/li>\n<li>D. B. F. Dopamine Brain Food by Natural Stacks: dabiska kognit\u012bvo sp\u0113ju uzlabo\u0161ana.<\/li>\n<li>Vasileva, L. V., Saracheva, K. \u00c5., Ivanovska, M. V., Petrova, A. P., Sucouglu, E., Murdjeva, M. A., &amp; Getova-Spasova, D. P. (2017). Hroniskas \u0101rst\u0113\u0161anas ar Rhodiola Rosea L. un Curcuma Longa L. ekstraktiem labv\u0113l\u012bga ietekme uz hroniskam viegla stresa modelim pak\u013cautu dz\u012bvnieku imunoreaktivit\u0101ti. <em>Folia Medica<\/em>, <em>59<\/em>(4), 443-453.<\/li>\n<li>Tardner, P. (2024). Bromant\u0101ns: k\u0101p\u0113c visi run\u0101 par \u0161o kognit\u012bvo sp\u0113ju uzlabot\u0101ju?<\/li>\n<li>Shirane, M., &amp; Nakamura, K. (2001). Aniracet\u0101ms palielina kortik\u0101l\u0101 dopam\u012bna un seroton\u012bna izdal\u012b\u0161anos, izmantojot hol\u012bner\u0123iskos un glutam\u012bner\u0123iskos meh\u0101nismus SHRSP. <em>Smadze\u0146u izp\u0113te<\/em>, <em>916<\/em>(1-2), 211-221.<\/li>\n<li>Kuhman, D. J. Kognit\u012bv\u0101 veiktsp\u0113ja un garast\u0101voklis p\u0113c teakr\u012bnu saturo\u0161a uztura bag\u0101tin\u0101t\u0101ja, kofe\u012bna vai placebo uz\u0146em\u0161anas ar...<\/li>\n<li>Bhoite, V., &amp; Wagh, S. (2024). Uzlabot garast\u0101vokli ar Mucuna pruriens. <em>Farmakognozijas un fito\u0137\u012bmijas p\u0113tniec\u012bbas \u017eurn\u0101ls<\/em>, <em>16<\/em>(4), 278-281.<\/li>\n<li>Desai, D., Patel, J., Saiyed, F., Upadhyay, H., Kariya, P., &amp; Patel, J. (2024). Literat\u016bras p\u0101rskats par holistisko labsaj\u016btu un dopam\u012bna bado\u0161anos: integr\u0113ta pieeja. <em>Cureus<\/em>, <em>16<\/em>(6).<\/li>\n<li>Malicse, A. Lab\u0101kie dabiskie stimuli labv\u0113l\u012bgai smadze\u0146u \u0137\u012bmijai.<\/li>\n<li>Coccurello, R., &amp; Maccarrone, M. (2018). Hedonistiska \u0113\u0161ana un \"gar\u0161\u012bgais aplis\": no lip\u012bdu izcelsmes mediatoriem l\u012bdz dopam\u012bnam smadzen\u0113s un atpaka\u013c. <em>Neirolo\u0123ijas robe\u017eas<\/em>, <em>12<\/em>, 271<\/li>\n<li>Brown, O. (2020). Soci\u0101l\u0101, emocion\u0101l\u0101 un neirolo\u0123isk\u0101 ietekme, ko rada periodiska atsl\u0113g\u0161an\u0101s no soci\u0101lo mediju lieto\u0161anas. <em>Nepublic\u0113ts ma\u0123istra darbs]. Malone University. https:\/\/www. malone. edu\/files\/resources\/revised-final-thesis-2020. pdf.<\/em>.<\/li>\n<li>Yong, K. A. C. (2024). DOPAM\u012aNS: DRAUGS VAI IENAIDNIEKS. <em>M\u016bs\u0113jie inov\u0101cijas<\/em>, (2 (45)), 9-10.<\/li>\n<li>Tsai, H. Y., Chen, K. C., Yang, Y. K., Chen, P. S., Yeh, T. L., Chiu, N. T., &amp; Lee, I. H. (2011). Saules starojuma un saules iedarb\u012bbas rad\u012bt\u0101s cilv\u0113ka striat\u0101l\u0101 dopam\u012bna D2\/D3 receptoru pieejam\u012bbas vari\u0101cijas veseliem br\u012bvpr\u0101t\u012bgajiem. <em>Progress neirofizofarmakolo\u0123ij\u0101 un biolo\u0123iskaj\u0101 psihiatrij\u0101<\/em>, <em>35<\/em>(1), 107-110.<\/li>\n<\/ol>","protected":false},"excerpt":{"rendered":"<p>Satura r\u0101d\u012bt\u0101js. Kas ir dopam\u012bns?. 1 Dopam\u012bns k\u0101 neirotransmiters un hormons. 1 Dopam\u012bna \u0137\u012bmisk\u0101 daba. 2 Fiziolo\u0123isk\u0101s un biolo\u0123isk\u0101s \u012bpa\u0161\u012bbas. 2 Darb\u012bbas meh\u0101nisms. 2 Dopam\u012bna receptori.\u2026<\/p>","protected":false},"author":7908,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-29595","post","type-post","status-publish","format-standard","hentry","beh-no-thumb"],"_links":{"self":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/29595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/users\/7908"}],"replies":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/comments?post=29595"}],"version-history":[{"count":0,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/29595\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/media?parent=29595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/categories?post=29595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/tags?post=29595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}